10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to

Commission File No. 001-36894

SOLAREDGE TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-5338862
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
	1 HaMada Street Herziliya Pituach 4673335, Israel (Address of principal executive offices, zip code)
	972 (9) 957-6620
	(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  

Yes x No o

     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer o
Non-accelerated filer x	(Do not check if a smaller reporting company)	Smaller Reporting Company o

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  

Yes oNo x

As of  May 1, 2016, there were 40,730,849 shares of the registrant’s common stock, par value of $0.0001 per share, outstanding.

SOLAREDGE TECHNOLOGIES, INC.

FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2016

INDEX

PART I. FINANCIAL INFORMATION		3
ITEM 1	Financial Statements	3
Consolidated Balance Sheets as of March 31, 2016 (unaudited) and June 30, 2015		F-2
Consolidated Statements of Operations for the three and nine months ended March 31, 2016 and, 2015 (unaudited)		F-4
Consolidated Statements of Cash Flows for the three and nine months ended March 31, 2016 and 2015 (unaudited)		F-6
Notes to Unaudited Consolidated Financial Statements		F-8
ITEM 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
ITEM 3	Quantitative and Qualitative Disclosures About Market Risk	14
ITEM 4	Controls and Procedures	15
PART II. OTHER INFORMATION		15
ITEM 1	Legal Proceedings	15
ITEM 1A	Risk Factors	15
ITEM 2	Unregistered Sales of Equity Securities and Use of Proceeds	16
ITEM 3	Defaults upon Senior Securities	16
ITEM 4	Mine Safety Disclosures	16
ITEM 5	Other Information	16
ITEM 6	Exhibits	17
EXHIBIT INDEX		17

2

PART I. FINANCIAL INFORMATION

ITEM 1FINANCIAL STATEMENTS 

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES.

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2016

IN U.S. DOLLARS

UNAUDITED

INDEX

	Page
Condensed Consolidated Balance Sheets as of March 31, 2016 (unaudited) and June 30, 2015	F- 2 - F - 3
Condensed Consolidated Statements of Operations for the Three and the Nine Months Ended March 31, 2016 and 2015 (unaudited)	F - 4
Condensed Consolidated Statements of Comprehensive Income for the Three and the Nine Months Ended March 31, 2016 and 2015 (unaudited)	F - 5
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2016 and 2015 (unaudited)	F - 6 - F - 7
Notes to the Condensed Consolidated Financial Statements (unaudited)	F - 8 - F - 28

3

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

U.S. dollars in thousands (except share and per share data)

	March 31,		June 30,
	2016		2015
	Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	84,070	$	144,750
Restricted cash		944		3,639
Marketable Securities		44,059		-
Trade receivables, net		56,145		35,428
Prepaid expenses and other accounts receivable		18,613		32,645
Inventories		85,514		73,950
Total current assets		289,345		290,412
PROPERTY AND EQUIPMENT, NET		26,213		14,717
LONG-TERM ASSETS:
Long-term marketable securities		43,151		-
Long-term prepaid expenses and lease deposits		440		529
Deferred tax assets, net		6,486		-
Intangible assets, net		737		-
		50,814		529
Total assets	$	366,372	$	305,658

The accompanying notes are an integral part of the consolidated financial statements.

F - 2

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

U.S. dollars in thousands (except share and per share data)

	March 31,			June 30,
	2016			2015
	Unaudited
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables	$	45,138		$	80,684
Employees and payroll accruals		12,358			6,814
Warranty obligations		13,510			9,431
Deferred revenues		2,642			1,676
Accrued expenses and other accounts payable		7,797			6,987
Total current liabilities		81,445			105,592
LONG-TERM LIABILITIES
Warranty obligations		33,149			22,448
Deferred revenues		13,266			8,289
Lease incentive obligation		2,265			2,385
Total long-term liabilities		48,680			33,122
COMMITMENTS AND CONTINGENT LIABILITIES
STOCKHOLDERS’ EQUITY:
Share capital
Common stock of $0.0001 par value - Authorized: 125,000,000 shares as of March 31, 2016 (unaudited) and June 30, 2015; issued and outstanding: 40,684,496 and 39,297,539 shares as of March 31, 2016 (unaudited) and June 30, 2015, respectively.		4			4
Additional paid-in capital		296,480			287,152
Accumulated other comprehensive income (loss)		417			(222	)
Accumulated deficit		(60,654	)		(119,990	)
Total stockholders’ equity		236,247			166,944
Total liabilities and stockholders’ equity	$	366,372		$	305,658

The accompanying notes are an integral part of the consolidated financial statements.

F - 3

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

U.S. dollars in thousands (except share and per share data)

	Three months ended March 31,					Nine months ended March 31,
	2016		2015			2016			2015
	Unaudited					Unaudited
Revenues	$	125,205	$	86,399		$	365,091		$	226,658
Cost of revenues		84,471		62,698			252,248			173,146
Gross profit		40,734		23,701			112,843			53,512
Operating expenses:
Research and development, net		8,709		5,490			23,999			15,317
Sales and marketing		8,826		6,422			25,903			17,541
General and administrative		3,460		1,990			9,066			4,270
Total operating expenses		20,995		13,902			58,968			37,128
Operating income		19,739		9,799			53,875			16,384
Financial income (expenses), net		2,029		(3,436	)		998			(3,378	)
Income before taxes on income		21,768		6,363			54,873			13,006
Taxes on income (tax benefit)		969		398			(4,463	)		1,146
Net income	$	20,799	$	5,965		$	59,336		$	11,860
Net basic earnings per share of common stock	$	0.52	$	0.01		$	1.49		$	0.02
Net diluted earnings per share of common stock	$	0.47	$	0.01		$	1.34		$	0.01
Weighted average number of shares used in computing net basic earnings per share of common stock		40,362,093		2,822,893			39,725,227			2,817,090
Weighted average number of shares used in computing net diluted earnings per share of common stock		44,577,901		7,099,046			44,347,071			5,534,903

The accompanying notes are an integral part of the consolidated financial statements.

F - 4

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)

U.S. dollars in thousands

	Three months ended March 31,						Nine months ended March 31,
	2016			2015			2016			2015
	Unaudited						Unaudited
Net income	$	20,799		$	5,965		$	59,336		$	11,860
Other comprehensive income (loss):
Available-for-sale securities:
Changes in unrealized losses, net of tax benefit		87			-			6			-
Reclassification adjustments for losses included in net income		1			-			1			-
Net change		88			-			7			-
Cash flow hedges:
Changes in unrealized gains, net of tax expense		668			-			745			-
Reclassification adjustments for gains, net of tax expense included in net income		(33	)		-			(35	)		-
Net change		635			-			710			-
Foreign currency translation adjustments, net		(13	)		(102	)		(78	)		(202	)
Other comprehensive income (loss)		710			(102	)		639			(202	)
Comprehensive income	$	21,509		$	5,863		$	59,975		$	11,658

The accompanying notes are an integral part of the consolidated financial statements.

F - 5

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

U.S. dollars in thousands

	Nine months ended March 31,
	2016			2015
	Unaudited
Cash flows provided by (used in) operating activities:
Net income	$	59,336		$	11,860
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		2,601			1,647
Amortization of intangible assets		63			-
Amortization of premiums on available-for-sale marketable securities		209			-
Stock-based compensation related to employees and non-employees consultants stock options		6,689			1,750
Financial income, net related to term loan		-			(992	)
Remeasurement of warrants to purchase preferred and common stock		-			2,065
Changes in assets and liabilities:
Inventories		(11,446	)		(39,071	)
Prepaid expenses and other accounts receivable		13,186			(12,198	)
Trade receivables, net		(20,681	)		(25,993	)
Deferred tax assets, net		(6,627	)		-
Trade payables		(35,554	)		39,604
Employees and payroll accruals		5,517			883
Warranty obligations		14,780			9,718
Deferred revenues		5,942			2,116
Accrued expenses and other accounts payable		497			2,733
Lease incentive obligation		(120	)		2,243
Net cash provided by (used in) operating activities		34,392			(3,635	)
Cash flows used in investing activities:
Purchase of property and equipment		(11,545	)		(8,254	)
Purchase of intangible assets		(800	)		-
Decrease (increase) in restricted cash		2,695			(1,973	)
Decrease (increase) in short and long-term lease deposits		23			(24	)
Purchases of available-for-sale marketable securities		(88,883	)		-
Maturities of available-for-sale marketable securities		1,000			-
Net cash used in investing activities		(97,510	)		(10,251	)

The accompanying notes are an integral part of the consolidated financial statements.

F - 6

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Cont.) U.S. dollars in thousands

	Nine months ended March 31,
	2016			2015
	Unaudited
Cash flows from financing activities:
Proceeds from short-term bank loans		-			23,000
Repayments of short term loan		-			(36,326	)
Repayments of term loan		-			(5,919	)
Proceeds from issuance of stock		-			24,712
Proceeds from IPO, net		-			133,944
Proceeds from exercise of employees and non-employees consultants stock options		2,639			46
Net cash provided by financing activities		2,639			139,457
Increase (decrease) in cash and cash equivalents		(60,479	)		125,571
Cash and cash equivalents at the beginning of the period		144,750			9,754
Erosion due to exchange rate differences		(201	)		(121	)
Cash and cash equivalents at the end of the period	$	84,070		$	135,204
Supplemental disclosure of non-cash financing activities:
Issuance expenses not paid in cash		-		$	2,489

The accompanying notes are an integral part of the consolidated financial statements.

F - 7

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 1:- GENERAL

a. SolarEdge Technologies, Inc. (the “Company”) and its subsidiaries design, develop, and sell an intelligent inverter solution designed to maximize power generation at the individual photovoltaic (“PV”) module level while lowering the cost of energy produced by the solar PV system and providing comprehensive and advanced safety features. The Company’s products consist mainly of (i) power optimizers designed to maximize energy throughput from each and every module through constant tracking of Maximum Power Point individually per module, (ii) inverters which invert direct current (DC) from the PV module to alternating current (AC) and (iii) a related cloud-based monitoring platform, that collects and processes information from the power optimizers and inverters of a solar PV system to enable customers and system owners, as applicable, to monitor and manage the solar PV systems. The Company operates its business itself and through its wholly-owned subsidiaries: SolarEdge Technologies Ltd. in Israel; SolarEdge Technologies GmbH in Germany; SolarEdge Technologies (China) Co., Ltd in China; SolarEdge Technologies (Australia) PTY Ltd. in Australia; SolarEdge Technologies (Canada) Ltd. in Canada; SolarEdge Technologies (Holland) B.V. in the Netherlands; SolarEdge Technologies (UK) Ltd in United Kingdom; SolarEdge Technologies (Japan) Co., Ltd. in Japan, SolarEdge Technologies (France) SARL in France, SolarEdge Technologies Italy S.R.L. in Italy and SolarEdge Technologies (Bulgaria) Ltd. in Bulgaria (collectively, the “subsidiaries”). Except for SolarEdge Technologies Ltd in Israel, which carries out the research and development, management of manufacturing, global sales and support and management activities, the other subsidiaries are engaged solely in selling, marketing and support activities.  The Company was incorporated in Delaware in August 2006 and began commercial sale of its products in January 2010.

b. Recent accounting pronouncements:   Inventory:
In July 2015, the Financial Accounting Standards Board (“FASB”) issued “ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory”, which changes the measurement principles for inventory from the lower of cost or market to the lower of cost and net realizable value. Net realizable value is defined as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.” ASU 2015-11 eliminates the guidance that required entities to consider replacement cost or net realizable value less an approximately normal profit margin in the subsequent measurement of inventory when cost is determined on a first-in, first-out or average cost basis. The provisions of ASU 2015-11 are effective for public entities with fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the impact of ASU 2015-11 on its consolidated financial position, consolidated results of operations, and consolidated cash flows

F - 8

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 1:-  GENERAL (Cont.)

Deferred Taxes:

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes, which will require that the presentation of deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company has adopted this guidance effective December 31, 2015. The adoption only impacted the presentation in its consolidated financial statements and related disclosure. No prior periods were retroactively adjusted.

c. The significant accounting policies applied in the Company’s audited annual consolidated financial statements as of June 30, 2015 are applied consistently in these financial statements.

d. Basis of Presentation:   The accompanying unaudited consolidated interim financial statements have been prepared in accordance with Article 10 of Regulation S-X, “Interim Financial Statements” and the rules and regulations for Form 10-Q of the Securities and Exchange Commission (the “SEC”). Pursuant to those rules and regulations, the Company has condensed or omitted certain information and footnote disclosure it normally includes in its annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly present its consolidated financial position, results of operations and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the 2015 consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for its fiscal year ended June 30, 2015 filed with the SEC on August 20, 2015 (the “2015 Form 10-K”). There have been no changes in the significant accounting policies from those that were disclosed in the audited consolidated financial statements for the fiscal year ended June 30, 2015 included in the 2015 Form 10-K.

e. The Company depends on two contract manufacturers and several limited or single source component suppliers. Reliance on these vendors makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs.   Two vendors collectively account for 72% (unaudited) and 79% of the Company’s total trade payables as of March 31, 2016 (unaudited) and June 30, 2015, respectively.

F - 9

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 1:-  GENERAL (Cont.)

f. Marketable Securities:   Marketable securities consist of corporate and governmental bonds. The Company determines the appropriate classification of marketable securities at the time of purchase and re-evaluates such designation at each balance sheet date. In accordance with FASB ASC No. 320 “Investments- Debt and Equity Securities”, the Company classifies marketable securities as available-for-sale. Available-for-sale securities are stated at fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss), a separate component of stockholders’ equity, net of taxes. Realized gains and losses on sales of marketable securities, as determined on a specific identification basis, are included in financial income (expenses), net. The amortized cost of marketable securities is adjusted for amortization of premium and accretion of discount to maturity, both of which, together with interest, are included in financial income (expenses), net. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term.
The Company recognizes an impairment charge when a decline in the fair value of its investments in debt securities below the cost basis of such securities is judged to be other-than-temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company’s intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. If the Company does not intend to sell the security or it is not more likely than not that it will be required to sell the security before it recovers in value, the Company must estimate the net present value of cash flows expected to be collected. If the amortized cost exceeds the net present value of cash flows, such excess is considered a credit loss and an other-than-temporary impairment has occurred.  For securities that are deemed other-than-temporarily impaired (“OTTI”), the amount of impairment is recognized in the statement of operations and is limited to the amount related to credit losses, while impairment related to other factors is recognized in other comprehensive income (loss). The Company did not recognize OTTI on its marketable securities during the nine months ended on March 31, 2016.

g. Derivative financial instruments:   The Company accounts for derivatives and hedging based on ASC 815 (“Derivatives and Hedging”). ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship.

F - 10

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 1:-  GENERAL (Cont.)

To protect against the increase in value of forecasted foreign currency cash flows resulting from salary and lease payments of its Israeli facilities denominated in the Israeli currency, the New Israeli Shekel (“NIS”), during the three and nine months ended March 31, 2016, the Company instituted a foreign currency cash flow hedging program. The Company hedges portions of the anticipated payroll and lease payments denominated in NIS for a period of one to twelve months with hedging contracts. Accordingly, when the dollar strengthens against the foreign currencies, the decline in present value of future foreign currency expenses is offset by losses in the fair value of the hedging contracts. Conversely, when the dollar weakens, the increase in the present value of future foreign currency cash flows is offset by gains in the fair value of the hedging contracts. These hedging contracts are designated as cash flow hedges, as defined by ASC 815 and are all effective hedges of these expenses.

In accordance with ASC 815, for derivative instruments that are designated and qualify as a cash flow hedge (i.e. hedging the exposure to variability in expected future cash flows that is attributable to a particular risk), the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Any gain or loss on a derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item is recognized in current earnings during the period of change.

In addition to the above mentioned cash flow hedges transactions, the Company also entered into derivative instrument arrangements to hedge the Company’s exposure to currencies other than the U.S. dollar. These derivative instruments are not designated as cash flows hedges, as defined by ASC 815, and therefore all gains and losses, resulting from fair value remeasurement, were recorded immediately in the statement of operations, as financial income (expenses).

As of March 31, 2016, the Company entered into forward contracts and put and call options to sell U.S. dollars and Euros in the amount of $19,547 and €2,500,000, respectively. These hedging contracts do not contain any credit-risk-related contingency features. See Note 6 for information on the fair value of these hedging contracts.

The fair value of derivative assets and derivative liabilities as of March 31, 2016 was $854 and $5, respectively which was recorded in other accounts receivable and prepaid expenses in the consolidated balance sheets.

The amount recorded as gain in the cost of revenues expenses under the consolidated statements of operations for the three and the nine months ended March 31, 2016 (unaudited) resulted from the above referenced hedging transactions was $8.

F - 11

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 1:- GENERAL (Cont.)

The amount recorded as gain in the research and development, net expenses under the consolidated statements of operations for the three and the nine months ended March 31, 2016 (unaudited) resulted from the above referenced hedging transactions was $18.

The amount recorded as gain in the sales and marketing expenses under the consolidated statements of operations for the three and the nine months ended March 31, 2016 (unaudited) resulted from the above referenced hedging transactions was $11.

The amount recorded as gain in the general and administrative expenses under the consolidated statements of operations for the three and the nine months ended March 31, 2016 (unaudited) resulted from the above referenced hedging transactions was $3 and $6, respectively.

The fair value of the outstanding derivative instruments as of March 31, 2016 (unaudited) and June 30, 2015 is summarized below:

		Fair Value of Derivative Instruments
	Balance Sheet Location	As of March 31, 2016 (unaudited)		As of June 30, 2015
Derivative Assets
Foreign exchange      forward contracts      and put and call options	Prepaid expenses and other accounts receivable (*)		849		859
Total			849		859

(*) Estimated to be reclassified into earnings until December 31, 2016.

F - 12

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 1:- GENERAL (Cont.)

The effect of derivative instruments in cash flow hedging transactions on income and other comprehensive income (“OCI”) for the three and the nine months ended March 31, 2016 and 2015 is summarized below:

	Gains on Derivatives Recognized in OCI		Gains on Derivatives Recognized in OCI
	for the three months ended		for the nine months ended
	March 31,		March 31,
	2016	2015	2016	2015
	(unaudited)		(unaudited)
Foreign exchange      forward contracts      and put and call      options	668	-	745	-

	Gains Reclassified from OCI into Income		Gains Reclassified from OCI into Income
	for the three months ended		for the nine months ended
	March 31,		March 31,
	2016	2015	2016	2015
	(unaudited)		(unaudited)
Foreign exchange      forward contracts      and put and call      options	33	-	35	-

h. Intangible assets:

On March 9, 2015, the Company and Beacon Power LLC, a Delaware limited liability company (“Beacon”) entered into a patent purchase agreement under which the Company agreed to purchase all rights in the patents. In July 2015, the Company completed the purchase of the patents for $800.

The patents are stated at cost, net of accumulated amortization. Amortization is calculated by the straight-line method over 10 years, which represents the estimated useful lives of the patents.

Amortization expenses for the three and the nine months ended March 31, 2016 (unaudited) were $21 and $63, respectively.

F - 13

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 1:- GENERAL (Cont.)

i. Accumulated other comprehensive income (loss):

The following table summarizes the changes in accumulated balances of other comprehensive income (loss), net of taxes, for the three months ended March 31, 2016 (unaudited):

	Unrealized gains (losses) on available-for-sale marketable securities			Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total
Beginning balance		(81	)		75			(287	)		(293	)
Other comprehensive income (loss) before reclassifications		87			668			(13	)		742
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1			(33	)		-			(32	)
Net current period other comprehensive income (loss)		88			635			(13	)		710
Ending balance		7			710			(300	)		417

The following table summarizes the changes in accumulated balances of other comprehensive loss, net of taxes, for the nine months ended March 31, 2016 (unaudited):

	Unrealized gains (losses) on available-for-sale marketable securities		Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total
Beginning balance		-		-			(222	)		(222	)
Other comprehensive income (loss) before reclassifications		6		745			(78	)		673
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1		(35	)		-			(34	)
Net current period other comprehensive income (loss)		7		710			(78	)		639
Ending balance		7		710			(300	)		417

F - 14

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 2:- MARKETABLE SECURITIES

The following is a summary of available-for-sale marketable securities at March 31, 2016 (unaudited):

	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair value
Corporate bonds	$	82,183	$	55	$	36	$	82,202
Governmental bonds	$	5,015	$	3	$	10	$	5,008
	$	87,198	$	58	$	46	$	87,210

As of June 30, 2015, the Company had no investments in marketable securities.

The amortized cost of available-for-sale marketable securities at March 31, 2016, by contractual maturities, is shown below:

	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair value
Due in one year or less	$	44,050	$	21	$	12	$	44,059
Due after one year to two years	$	43,148	$	37	$	34	$	43,151
	$	87,198	$	58	$	46	$	87,210

As of March 31, 2016, management believes the impairments are not other than temporary and therefore the impairment losses were recorded in accumulated other comprehensive income (loss). The Company has no intent to sell these securities and it is more likely than not that the Company will not be required to sell these securities prior to the recovery of the entire amortized cost basis.

As of March 31, 2016 (unaudited), there was 32 securities in a loss position.

The total fair value of marketable securities with outstanding unrealized losses as of March 31, 2016 (unaudited) amounted to $40,147, while the unrealized losses for these marketable securities amounted to $46.

F - 15

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 3:- INVENTORIES

	March 31, 2016		June 30, 2015
	(unaudited)
Raw materials	$	10,639	$	14,405
Finished goods		74,875		59,545
	$	85,514	$	73,950

NOTE 4:- WARRANTY OBLIGATIONS

Changes in the Company’s product warranty liability for the nine months ended March 31, 2016 and 2015 were as follows:

	Nine months ended March 31,
	2016			2015
	(unaudited)
Balance, at beginning of period	$	31,879		$	18,181
Additions and adjustments to cost of revenues		21,250			13,456
Usage and current warranty expenses		(6,470	)		(3,738	)
Balance, at end of period		46,659			27,899
Less current portion		13,510			7,661
Long term portion	$	33,149		$	20,238

NOTE 5:- REVOLVING CREDIT LINE

In June 2011, the Company entered into an agreement for a revolving line of credit from a bank lender (the "Bank Lender").

On February 17, 2015, the Company amended and restated the agreement with the Bank Lender for its revolving line of credit, which permits aggregate borrowings of up to $40 million in an amount not to exceed 80% of the eligible accounts receivable and bears interest, payable monthly, at the Bank Lender’s prime rate plus a margin of 0.5% to 2.0%. The Company’s revolving line of credit will terminate, and outstanding borrowings will be payable, on December 31, 2016.

F - 16

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 5:- REVOLVING CREDIT LINE (Cont.)

In connection with the revolving line of credit, the Company granted the Bank Lender security interests in substantially all of the Company’s assets, including a first-priority security interest in the Company’s trade receivables, cash and cash equivalents. Financial covenants contained in the amended and restated agreement require the Company to maintain EBITDA and liquidity at specified levels.

The Company is required to maintain liquidity (defined as unrestricted and unencumbered cash, plus availability in the amended and restated agreement) of $6,750.

The amended and restated agreement also contains covenants that restrict the Company’s ability to dispose of assets, engage in business combinations (or permit a subsidiary to engage in business combinations), grant liens, borrow money, or pay dividends.

As of March 31, 2016 (unaudited) and June 30, 2015, the Company was in compliance with all applicable covenants in the amended and restated agreement.

As of March 31, 2016 (unaudited), the Company had no outstanding borrowings pursuant to this revolving line of credit.

NOTE 6:- FAIR VALUE MEASUREMENTS

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level to classify them for each reporting period. There have been no transfers between fair value measurements levels during the nine months ended March 31, 2016.

The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value:

Level 1- Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2- Include other inputs that are directly or indirectly observable in the marketplace.

Level 3- Unobservable inputs which are supported by little or no market activity.

F - 17

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 6:- FAIR VALUE MEASUREMENTS (Cont.)

The following table sets forth the Company’s assets that were measured at fair value as of March 31, 2016 (unaudited) by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	March 31, 2016 (unaudited)		Level 1		Level 2		Level 3
Cash equivalents:
Money market mutual funds	$	17,520	$	17,520		-		-
Derivative instruments asset	$	849		-	$	849		-
Short-term marketable securities:
Corporate bonds	$	43,055		-	$	43,055		-
Governmental bonds	$	1,004		-	$	1,004		-
Long-term marketable securities:
Corporate bonds	$	39,147		-	$	39,147		-
Governmental bonds	$	4,004		-	$	4,004		-

The following table sets forth the Company’s assets that were measured at fair value as of June 30, 2015 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	June 30, 2015		Level 1		Level 2		Level 3
Derivative instruments asset	$	859		-	$	859		-

In addition to the assets described above, the Company’s financial instruments also include cash and cash equivalents, restricted and short-term deposits, trade receivables, other accounts receivable, trade payables, accrued expenses and other payables. The fair value of these financial instruments was not materially different from their carrying values on Mach 31, 2016 due to the short-term maturity of these instruments.

F - 18

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 7:- LEASE INCENTIVE OBLIGATION

The Company has an operating lease agreement for a building in Herziliya, Israel. In connection with this lease, the Company and its third party lessor (the "Lessor"), agreed that the Lessor would reimburse approximately $2,938 for certain leasehold improvements made by the Company.

As of March 31, 2016 (unaudited), the Company received in cash $2,917 from the Lessor in connection with such leasehold improvements. These leasehold improvements are accounted for as a lease incentive obligation, which is recorded under long-term liabilities, net of the current portion recorded in accrued expenses and other accounts payable under current liabilities. The lease incentive obligation is being amortized over the life of the lease and as a reduction to rent expense. As of March 31, 2016, the net amortized amount of lease incentive obligation recorded under long-term liabilities is $2,265.

NOTE 8:- COMMITMENTS AND CONTINGENT LIABILITIES

a. Lease commitments:

The Company and its subsidiaries lease their operating facilities under non-cancelable operating lease agreements, which expire over the next nine years, with the last ending in December 2024.

The future minimum lease commitments of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises that are in effect as of March 31, 2016 (unaudited), are as follows:

Year ended June 30,	(unaudited)
2016		598
2017		2,252
2018		2,148
2019		2,003
2020 and thereafter		8,707
		15,708

Rent expenses for the nine months ended March 31, 2016 (unaudited) and 2015 (unaudited) were approximately $1,653 and $1,222, respectively.

F - 19

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 8:- COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)

b. Guarantees:

As of March 31, 2016 (unaudited), contingent liabilities exist regarding guarantees in the amount of $631, $53 and $85 in respect of office rent lease agreements, customs transactions and credit card limits, respectively.

c. Royalty and Governmental commitments:

As of March 31, 2016 (unaudited), the aggregate contingent liability to the Binational Industrial Research and Development Foundation (BIRD-F) amounted to approximately $1,132 which would be payable by the Company if it ever did generate revenues from such project.

As of March 31, 2016 (unaudited), the aggregate contingent liability to the Office of the Chief Scientist (the OCS) amounted to $782.

d. Contractual purchase obligations:

The Company has contractual obligations to purchase certain goods and raw materials. These contractual purchase obligations relate to certain inventories held by contract manufacturers and purchase orders initiated by the contract manufacturers and suppliers, which cannot be canceled without penalty. The Company utilizes third parties to manufacture its products. In addition, it acquires raw materials or other goods and services, including product components, by issuing to suppliers authorizations to purchase based on its projected demand and manufacturing needs. As of March 31, 2016 (unaudited), the Company had non-cancelable purchase obligations totaling approximately $84,275, of which the Company already recorded a provision for loss in the amount of $1,860.

e. Legal claims:

From time to time, the Company may be involved in various claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. These accruals are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular matter.

NOTE 9:- STOCK CAPITAL

a. On March 23, 2015, the Company's board of directors and the requisite holders of the Company's capital stock consented to a 1-for-3 reverse stock split of the Company's common stock. As a result of the reverse stock split, (i) every 3 shares of authorized, issued and outstanding common stock was decreased to one share of authorized, issued and outstanding common stock, (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased on a 1-for-3 basis, (iii) all share prices and exercise prices were proportionately increased. All of the share numbers, share prices, and exercise prices have been adjusted within these consolidated financial statements, on a retroactive basis, to reflect this 1-for-3 reverse stock split.

F - 20

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 9:- STOCK CAPITAL (Cont.)

b. Common Stock:

	Authorized		Issued and outstanding
	Number of shares
	March 31, 2016	June 30, 2015	March 31, 2016	June 30, 2015
	(unaudited)		(unaudited)
Stock of $0.0001 par value:
Common stock	125,000,000	125,000,000	40,684,496	39,297,539

c. Stock Incentive plans:

The Company’s 2007 Global Incentive Plan (the “2007 Plan”) was adopted by the board of directors on August 30, 2007. On March 31, 2015, upon consummation of the Company’s Initial Public Offering (“IPO”), the 2007 Plan was terminated and no further awards will be granted thereunder. All outstanding awards will continue to be governed by their existing terms and 379,358 available options for future grant were transferred to the Company’s 2015 Global Incentive Plan (the “2015 Plan”) and are reserved for future issuances under the 2015 Plan.

The 2015 Plan became effective upon the consummation of the IPO. The 2015 Plan provides for the grant of options, RSUs and other share-based awards to directors, employees, officers and consultants of the Company and its subsidiaries. The Share Reserve will automatically increase on January 1st of each year during the term of the 2015 Plan commencing on January 1st of the year following the year in which the 2015 Plan becomes effective in an amount equal to five percent (5%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year; provided, however, that our board of directors may provide that there will not be a January 1st increase in the Share Reserve in a given year or that the increase will be less than five percent (5%) of the shares of common stock outstanding on the preceding December 31st.

The aggregate maximum number of shares of common stock that may be issued on the exercise of incentive stock options is ten million (10,000,000).

F - 21

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 9:- STOCK CAPITAL (Cont.)

As of March 31, 2016 (unaudited), a total of 3,827,117 (unaudited) shares of common stock were reserved for issuance under the 2015 Plan (the “Share Reserve”).

As of March 31, 2016 (unaudited), an aggregate of 2,731,852 shares of common stock are available for future grant under the 2015 Plan.

d. Options granted to employees and members of the board of directors:

A summary of the activity in the options granted to employees and members of the board of directors for the nine months ended March 31, 2016 (unaudited) and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	Options			price		in years		value
Outstanding as of July 1, 2015		6,034,782			3.14		7.06		200,438
Granted		228,800			25.09
Exercised		(1,230,923	)		2.05
Forfeited or expired		(46,971	)		3.86
Outstanding as of March 31, 2016		4,985,688			4.41		6.75		103,375
Vested and expected to vest as of March 31, 2016		4,798,492			4.33		6.73		99,877
Exercisable as of March 31, 2016		3,099,118			2.88		5.65		68,974

The aggregate intrinsic value represents the total intrinsic value (the difference between the fair value of the Company’s common stock as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period. The total intrinsic value of options exercised during the nine months ended on March 31, 2016 (unaudited) was $27,602.

The weighted average grant date fair values of options granted to employees and executive directors during the nine months ended March 31, 2016 (unaudited) was $25.09.

F - 22

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 9:- STOCK CAPITAL (Cont.)

The options outstanding as of March 31, 2016 (unaudited) have been separated into exercise price ranges as follows:

			Weighted		Options		Weighted
	Outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	March 31,		contractual		March 31,		contractual
price	2016		life in years		2016		life in years
$0.87 - $1.50		770,940		2.89		770,940		2.89
$1.68 - $2.46		1,465,040		5.49		1,408,292		5.46
$3.03 - $3.96		542,018		7.53		279,270		7.24
$5.01		1,945,562		8.66		602,296		8.66
$9.36		33,328		8.84		9,720		8.84
$25.09		228,800		9.39		28,600		9.39
		4,985,688		6.75		3,099,118		5.65

e. A summary of the activity in the RSUs granted to employees and members of the board of directors for the nine months ended March 31, 2016 (unaudited), is as follows:

	No. of Options			Weighted average grant date fair value
Unvested as of July 1, 2015		67,440			25.09
Granted		807,656			24.45
Vested		(112,591	)		24.57
Forfeited		(40,965	)		24.07
Unvested as of March 31, 2016		721,540			24.38

F - 23

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 9:- STOCK CAPITAL (Cont.)

f.  Options and RSUs issued to non-employee consultants:

The Company has granted options and RSUs to non-employee consultants as of March 31, 2016 (unaudited) as follows:

	Outstanding				Exercisable
	as of				as of
Issuance	March 31,		Exercise		March 31,		Exercisable
date	2016		price		2016		through
July 31, 2008		33,333		0.87		33,333	July 31, 2018
October 24, 2012		5,166		2.46		4,333	October 24, 2022
January 23, 2013		3,333		3.03		2,778	January 23, 2023
January 27, 2014		4,698		3.51		2,226	January 27, 2024
May 1, 2014		6,000		3.51		3,167	May 1, 2024
September 17, 2014		10,830		3.96		4,790	September 17, 2024
October 29, 2014		5,788		5.01		1,010	October 29, 2024
August 19, 2015		28,167		0.00		-
November 8, 2015		4,167		0.00		-
		101,482				51,637

The Company had accounted for its options and RSUs granted to non-employee consultants under the fair value method of ASC 505-50. In connection with the grant of options and RSUs to non-employee consultants, the Company recorded stock compensation expenses in the three months ended March 31, 2016 (unaudited) and 2015 (unaudited) in the amounts $91, and $228, respectively, and stock compensation expenses in the nine months ended March 31, 2016 and 2015 in the amounts $464 and $331, respectively

F - 24

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 9:- STOCK CAPITAL (Cont.)

g. Stock-based compensation expense for employees and consultants:

The Company recognized stock-based compensation expenses related to options and RSUs granted to employees and non-employees in the consolidated statement of operations for the three and six months ended on March 31, 2016 (unaudited) and 2015 (unaudited), as follows:

	Three months ended March 31,				Nine months ended March 31,
	2016		2015		2016		2015
Cost of revenues	$	246	$	140	$	635	$	254
Research and development		724		183		1,637		449
Selling and marketing		842		292		2,207		545
General and administrative		819		355		2,210		502
Total stock-based compensation expense	$	2,631	$	970	$	6,689	$	1,750

As of March 31, 2016 (unaudited), there was a total unrecognized compensation expense of $26,384 related to non-vested equity-based compensation arrangements granted under the Company’s plans. These expenses are expected to be recognized during the period from April 1, 2016 through February 29, 2020.

NOTE 10:- INCOME TAXES

a. Taxes on income (tax benefit) are comprised as follows:

	Three months ended March 31,					Nine months ended March 31,
	2016			2015		2016			2015
	Unaudited					Unaudited
Current year taxes	$	1,069		$	398	$	2,380		$	1,146
Previous year taxes		-			-		(216	)		-
Deferred tax expense (income)		(100	)		-		(6,627	)		-
Taxes on income (tax benefit)	$	969		$	398	$	(4,463	)	$	1,146

F - 25

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 10:- INCOME TAXES (Cont.)

b. Deferred income taxes:

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

Significant components of the Company’s deferred tax liabilities and assets are as follows:

	March 31,		June 30,
	2016		2015
	(Unaudited)
Assets in respect of:
Carryforward tax losses	$	-	$	23,033
Research and Development carryforward expenses- temporary differences		4,488		5,173
Stock-based compensation		548		-
Other reserves		1,450		1,346
		6,486		29,552
Valuation allowance (1)		-		(29,552	)
Net deferred tax assets	$	6,486	$	-

(1) ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluated the net deferred tax assets for each separate tax entity. As of June 30, 2015, the Company concluded that it is not more likely than not that the net deferred tax assets will be realized and a full valuation allowance has been recorded against these assets. The Company's estimate of future book-taxable income considers available evidence, both positive and negative, about its operating businesses and investments, including an aggregation of individual projections for each significant operating business and investment, estimated apportionment factors for state and local taxing jurisdictions and includes all future years that the Company estimated it would have available net operating loss carryforwards.

During the second fiscal quarter of 2016, the Company determined that the positive evidence outweighs the negative evidence for deferred tax assets and concluded that these deferred tax assets are realizable on a "more likely than not" basis. This determination was mainly due to expected future results of positive operations and earnings history.

NOTE 11:- BASIC AND DILUTED NET EARNINGS PER SHARE

Basic net earnings per share is computed by dividing the net earnings by the weighted-average number of shares of common stock outstanding during the period.

The total weighted average number of shares of common stock related to the outstanding stock options, convertible preferred stock and warrants to purchase convertible preferred stock and common stock, excluded from the calculation of diluted net earnings per share due to their anti-dilutive effect, was 0 and 28,351,707 for the three months ended March 31, 2016 (unaudited) and 2015 (unaudited), respectively and 12,945 and 27,378,784 for the nine months ended March 31, 2016 (unaudited) and 2015 (unaudited), respectively

Basic and diluted earnings per share is presented in conformity with the two-class method for participating securities for the periods prior to their conversion. Under this method, the earnings per share for each class of shares are calculated assuming 100% of the Company's earnings are distributed as dividends to each class of shares based on their contractual rights.

F - 26

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 11:- BASIC AND DILUTED NET EARNINGS PER SHARE (Cont.)

The following table presents the computation of basic and diluted net earnings per share for the periods presented:

	Three months ended March 31,					Nine months ended March 31,
	2016		2015			2016		2015
	(unaudited)					(unaudited)
Numerator:
Net income		20,799		5,965			59,336		11,860
Dividends accumulated for the period		-		(5,923	)		-		(11,817	)
Net income available to holders of common stock		20,799		42			59,336		43
Denominator:
Shares used in computing net earnings per share of common stock, basic		40,362,093		2,822,893			39,725,227		2,817,090
Numerator:
Net income		20,799		5,965			59,336		11,860
Dividends accumulated for the period		-		(5,872	)		-		(11,782	)
Net income available to holders of common stock		20,799		93			59,336		78
Denominator:
Shares used in computing net earnings per share of common stock, diluted		44,577,901		7,099,046			44,347,071		5,534,903

F - 27

SOLAREDGE TECHNOLOGIES, INC.

AND ITS SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

U.S. dollars in thousands (except share and per share data)

NOTE 12:- CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

a. For the three month period ended March 31, 2016 (unaudited), the Company had two major customers that accounted for approximately 26.7% of its consolidated revenues.

For the nine month period ended March 31, 2016 (unaudited), the Company had three major customers that accounted for approximately 34.9% of its consolidated revenues.

For the year ended June 30, 2015, the Company had one major customer that accounted for 24.6% of its consolidated revenues.

b. As of March 31, 2016 (unaudited), three customers accounted for 38.5% of the Company’s net accounts receivable and as of June 30, 2015, one customer accounted for 30.0% of the Company’s net accounts receivable.

F - 28

ITEM 2MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

Statements contained in this Form 10-Q or statements incorporated by reference from documents we have filed with the Securities and Exchange Commission may contain forward-looking statements that are based on our management’s expectations, estimates or projections beliefs and assumptions in accordance with information currently available to our management. Forward-looking statements should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this report. This discussion contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, technology developments, new products and services, financing and investment plans, dividend policy, competitive position, industry and regulatory environment, potential growth opportunities and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,” “seek,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or similar expressions and the negatives of those terms.

Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward looking statements. Given these uncertainties, you should not place undue reliance on forward looking statements. Also, forward looking statements represent our management’s beliefs and assumptions only as of the date of this filing. Important factors that could cause actual results to differ materially from our expectations include:

· our history of losses and limited period of profitability, which may not continue in the future;

· our limited operating history, which makes it difficult to predict future results;

· future demand for solar energy solutions;

· changes to net metering policies or the reduction, elimination or expiration of government subsidies and economic incentives for on-grid solar electricity applications;

· federal, state and local regulations governing the electric utility industry with respect to solar energy;

· the retail price of electricity derived from the utility grid or alternative energy sources;

· interest rates and supply of capital in the global financial markets in general and in the solar market specifically;

· competition, including introductions of power optimizer, inverter and solar PV system monitoring products by our competitors;

· developments in alternative technologies or improvements in distributed solar energy generation;

· historic cyclicality of industry and periodic downturns;

· defects or performance problems in our products;

· our ability to forecast demand for our products accurately and to match production with demand;

· our dependence on ocean transportation to deliver our products in a cost effective manner;

4

· our dependence upon a small number of outside contract manufacturers;

· capacity constraints, delivery schedules, manufacturing yields and costs of our contract manufacturers and availability of components;

· delays, disruptions and quality control problems in manufacturing;

· shortages, delays, price changes or cessation of operations or production affecting our suppliers of key components;

· business practices and regulatory compliance of our raw material suppliers;

· performance of distributors and large installers in selling our products;

· our customer’s financial stability, creditworthiness and debt leverage ratio;

· our ability to retain key personnel and attract additional qualified personnel;

· our ability to maintain our brand and to protect and defend our intellectual property;

· our ability to retain, and events affecting, our major customers;

· our ability to manage effectively the growth of our organization and expansion into new markets;

· our ability to successfully introduce new products and services;

· our ability to raise additional capital on favorable terms or at all;

· fluctuations in currency exchange rates;

· unrest, terrorism or armed conflict in Israel;

· general economic conditions in our domestic and international markets; and

· the other factors set forth under “Item 1A. Risk Factors” in “Part II-OTHER INFORMATION” section of this report.

Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Overview

We have invented an intelligent inverter solution that has changed the way power is harvested and managed in a solar photovoltaic (“PV”) system. Our direct current (“DC”) optimized inverter system is designed to maximize power generation at the individual PV module level while lowering the cost of energy produced by the solar PV system and providing comprehensive and advanced safety features. Our systems allow for superior power harvesting and module management by deploying power optimizers at each PV module while maintaining a competitive system cost by using a simplified DC AC inverter. Our systems are monitored through our cloud-based monitoring platform that enables lower system operating and maintenance (“O&M”) costs. We believe that these benefits, along with our comprehensive and advanced safety features, are highly valued by our customers.

As of March 31, 2016, we have shipped approximately 11.0 million power optimizers and 455,000 inverters. Approximately 231,639 installations, many of which may include multiple inverters, are currently connected to, and monitored through, our cloud-based monitoring platform. As of March 31, 2016, we have shipped approximately 2.9 GW of our DC optimized inverter systems. Our products are sold in approximately 42 countries, and are installed in solar PV systems in 91 countries.

5

As of March 31, 2016, approximately 13,099 indirect customers had registered with us through our cloud-based monitoring platform.

Our revenues for the nine months ended March 31, 2015 and 2016 were $226.7 million and $365.1 million, respectively. Gross margin was 23.6% and 30.9% for the nine months ended March 31, 2015 and 2016, respectively. Net income was $11.9 million and $59.3 million for the nine months ended March 31, 2015 and 2016, respectively.

Recent Developments

In January 2016, we announced the commercial availability of our StorEdgeTM solutions.  Our StorEdgeTM solution allows homeowners to maximimze self-consumption and to enable independence, by storing unusued PV power in a battery and allowing such power to be used by the homeowner when needed.  The StorEdgeTM solution is based on a single inverter for both PV power generation and storage.

Key Operating Metrics

In managing our business and assessing financial performance, we supplement the information provided by the financial statements with other operating metrics. These operating metrics are utilized by our management to evaluate our business, measure our performance, identify trends affecting our business and formulate projections. We use metrics relating to yearly shipments (inverters shipped, power optimizers shipped and megawatts shipped) to evaluate our sales performance and to track market acceptance of our products from year to year. We use metrics relating to monitoring (systems monitored) to evaluate market acceptance of our products and usage of our solution.

We provide the “megawatts shipped” metric, which is calculated based on nameplate capacity shipped, to show adoption of our system on a nameplate capacity basis. Nameplate capacity shipped is the maximum rated power output capacity of an inverter and corresponds to our financial results in that higher total capacities shipped are generally associated with higher total revenues. However, revenues increase with each additional unit, not necessarily each additional MW of capacity, sold. Accordingly, we also provide the “inverters shipped” and “power optimizers shipped” operating metrics.

	Three Months Ended March 31,				Nine Months Ended March 31,
	2016		2015		2016		2015
Inverters shipped		52,333		38,630		165,608		106,206
Power optimizers shipped		1,417,469		945,586		4,251,153		2,395,166
Megawatts shipped (1)		416		248		1,188		637

——————

(1) Calculated based on the aggregate nameplate capacity of inverters shipped during the applicable period. Nameplate capacity is the maximum rated power output capacity of an inverter as specified by the manufacturer.

Results of Operations

The results of operations presented below should be reviewed in conjunction with the consolidated financial statements and related notes included elsewhere in this report.

6

The following table sets forth selected consolidated statements of operations data for each of the periods indicated.

	Three Months Ended March 31,					Nine Months Ended March 31,
	2016		2015			2016			2015
	(In thousands)					(In thousands)
Revenues	$	125,205	$	86,399		$	365,091		$	226,658
Cost of revenues		84,471		62,698			252,248			173,146
Gross profit		40,734		23,701			112,843			53,512
Operating expenses:
Research and development, net		8,709		5,490			23,999			15,317
Sales and marketing		8,826		6,422			25,903			17,541
General and administrative		3,460		1,990			9,066			4,270
Total operating expenses		20,995		13,902			58,968			37,128
Operating income		19,739		9,799			53,875			16,384
Financial income (expenses), net		2,029		(3,436	)		998			(3,378	)
Income before taxes on income		21,768		6,363			54,873			13,006
Taxes on income (tax benefit)		969		398			(4,463	)		1,146
Net income	$	20,799	$	5,965		$	59,336		$	11,860

Comparison of the Three Months Ended March 31, 2016 and 2015

Revenues

	Three Months Ended March 31,				Three Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Revenues	$	125,205	$	86,399	$	38,806	44.9	%

Revenues increased by $38.8 million, or 44.9%, for the three months ended March 31, 2016 as compared to the three months ended March 31, 2015, primarily due to an increase in the number of systems sold in the U.S. market and certain countries in Europe. The number of power optimizers sold increased by approximately 0.6 million units, or 58.7%, from approximately 0.9 million units in the three months ended March, 2015 to approximately 1.5 million units in the three months ended March 31, 2016. The number of inverters sold increased by approximately 14,200 units, or 35.3%, from approximately 40,300 units in the three months ended March 31, 2015 to approximately 54,500 units in the three months ended March 31, 2016. Our blended average selling price per watt for units shipped decreased by $0.048, or 13.7%, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015, primarily due to (i) increased volumes of commercial products that are characterized by lower average selling prices per watt; (ii) price erosion in the overall inverter market; (iii) a change in our geographic mix, specifically in sales to Europe where the devaluation of the Euro against the U.S. Dollar in calendar 2015 reduced our average selling price when translated into U.S. Dollars; and (iv) a change in our customer mix, which included a higher portion of sales to large customers to whom we provide volume discounts.

Cost of Revenues and Gross Profit

	Three Months Ended March 31,				Three Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Cost of revenues	$	84,471	$	62,698	$	21,773	34.7	%
Gross profit	$	40,734	$	23,701	$	17,033	71.9	%

7

Cost of revenues increased by $21.8 million, or 34.7%, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015, primarily due to (i) an increase in the volume of products sold; (ii) an increase in personnel-related costs resulting from an increase in our operations and support headcount; (iii) increased warranty expenses and warranty accruals associated with the increase in our install base; and (iv) an inventory write off of $1.0 million related to unrecognized revenues from a customer that filed for bankruptcy. These increases were offset by reductions derived from increased efficiency in our supply chain, including a decrease in shiping costs associated with the reduced use of air freight. Gross profit as a percentage of revenue increased from 27.4% in the three months ended March 31, 2015 to 32.5% in the three months ended March 31, 2016, primarily due to reductions in per unit production costs, increased efficiency in our supply chain derived from the use of more ocean freight shipments rather than air shipments lower costs associated with warranty product replacements, and general economies of scale in our personnel-related costs and other reduction in costs associated with our support and operations departments.

Operating Expenses:

Research and Development, Net

	Three Months Ended March 31,				Three Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Research and development, net	$	8,709	$	5,490	$	3,219	58.6	%

Research and development, net increased by $3.2 million, or 58.6%, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015, primarily due to an increase in personnel-related costs of $2.4 million from higher  headcount. The increase in headcount reflects our continued investment in enhancing our existing products as well as activities associated with bringing new products to market. In addition, the use of external consultants and sub-contractors, expenses related to materials used for development and other overhead costs and deprecation expenses increased by $0.3 million, $0.2 million and $0.3 million, respectively, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015.

Sales and Marketing

	Three Months Ended March 31,				Three Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Sales and marketing	$	8,826	$	6,422	$	2,404	37.4	%

Sales and marketing expenses increased by $2.4 million, or 37.4%, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015, primarily due to an increase in personnel-related costs of $1.5 million due to an increase in headcount associated with supporting our growth in the U.S. and Europe. In addition, expenses related to trade shows and marketing activities and expenses associated with our worldwide sales offices, travel and other overhead costs increased by $0.5 million and $0.4 million, respectively, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015.

General and Administrative

	Three Months Ended March 31,				Three Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
General and administrative	$	3,460	$	1,990	$	1,470	73.9	%

8

General and administrative expenses increased by $1.5 million, or 73.9%, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015, primarily due to an increase in personnel-related costs of $0.7 million related to (i) higher headcount in the legal, finance, human resources, and information technology department functions required of a fast-growing public company and (ii) increased expenses related to equity-based compensation and changes in management compensation. In addition, costs related to being a public company, costs related to accounting, tax, legal and information systems consulting, costs related to the accrual of doubtful debts and other directly related overhead costs increased by $0.3 million, $0.2 million, $0.2 million, and $0.1 million, respectively, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015.

Financial income (expenses), net

	Three Months Ended March 31,					Three Months Ended March 31, 2015 to 2016
	2016		2015			Change
	(Dollars in thousands)
Financial income (expenses), net	$	2,029	$	(3,436	)	$	5,465	N/A

Financial income was $2.0 million in the three months ended March 31, 2016 as compared to financial expenses of $3.4 million in the three months ended March 31, 2015, primarily due to income of $2.0 million generated from foreign exchange fluctuations between the the Euro and the New Israeli Shekel against the U.S. Dollar in the three months ended March 31, 2016 compared to $0.5 million in expenses from foreign exchange fluctuations in the three months ended March 31, 2015, $2.2 million related to interest expenses on a term loan received from Kreos Capital IV (Expert Fund) Limited (“Kreos”) in December 2012 (the “Kreos Loan”) and the revolving line of credit from SVB (described below) and expensesrelated to re-measurement of certain warrants granted to Kreos in relation to the Kreos Loan in the three months ended March 31, 2015 as compared to no such expenses in the three months ended March 31, 2016 due to full repayment of the Kreos Loan and exercise of the warrants by Kreos. Additionally, $0.2 million interest income, net of accretion (amortization) of discount (premium) on marketable securities and time deposits were generated in the three months ended March 31, 2016 compared to none in the three months ended March 31, 2015. In addition, costs related to hedging transactions, and interest expenses decreased by $0.4 million and $0.1 million, respectively, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015.

Taxes on Income

	Three Months Ended March 31,				Three Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Taxes on income	$	969	$	398	$	571	143.5	%

Tax on income increased by $0.6 million in the three months ended March 31, 2016 compared to the three months ended March 31, 2015, primarily due to an increase of $0.7 million in current tax expenses for the three months ended March 31, 2016 compared to the three months ended March 31, 2015. In addition, deferred taxes decreased by $0.1 million for the three months ended March 31, 2016 compared to the three months ended March 31, 2015.

9

Net Income

	Three Months Ended March 31,				Three Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Net income	$	20,799	$	5,965	$	14,834	248.7	%

As a result of the factors discussed above, net income increased by $14.8 million, or 248.7%, in the three months ended March 31, 2016 as compared to the three months ended March 31, 2015.

Comparison of the Nine Months Ended March 31, 2016 and 2015

Revenues

	Nine Months Ended March 31,				Nine Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Revenues	$	365,091	$	226,658	$	138,433	61.1	%

Revenues increased by $138.4 million, or 61.1%, for the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015, primarily due to an increase in the number of systems sold in the U.S. and certain countries in Europe. The number of power optimizers sold increased by approximately 1.9 million units, or 78.3%, from approximately 2.4 million units in the nine months ended March 31, 2015 to approximately 4.3 million units in the nine months ended March 31, 2016. The number of inverters sold increased by approximately 59,200 units, or 55.0%, from approximately 107,600 units in the nine months ended March 31, 2015 to approximately 166,800 units in the nine months ended March 31, 2016. Our blended average selling price per watt for units shipped decreased by $0.048, or 13.4%, in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015, primarily due to (i) increased volumes of commercial products that are characterized by lower average selling prices per watt; (ii) decreased prices in the overall inverter market; (iii) a change in our geographic mix, specifically in sales to Europe where the devaluation of the Euro against the U.S. Dollar in calendar 2015 reduced our U.S. Dollar translated average selling price; and (iv) a change in our customer mix, which included a higher portion of sales to large customers to whom we provide volume discounts.

Cost of Revenues and Gross Profit

	Nine Months Ended March 31,				Nine Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Cost of revenues	$	252,248	$	173,146	$	79,102	45.7	%
Gross profit	$	112,843	$	53,512	$	59,331	110.9	%

Cost of revenues increased by $79.1 million, or 45.7%, in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015, primarily due to (i) an increase in product costs and logistics costs associated with the increased volume of products sold; (ii) an increase in personnel-related costs resulting from an increase in our operations and support headcount; and (iii) increased warranty expenses and warranty accruals. These increases were offset by reductions of shipping costs associated with the reduced use of air freight. Gross profit as a percentage of revenue increased from 23.6% in the nine months ended March 31, 2015 to 30.9% in the nine months ended March 31, 2016, primarily due to cost reductions in per unit product costs, an increased portion of ocean freight shipments in comparison to air shipments as well as other increased efficiency measures in our supply chain, lower costs associated with our warranty and warranty provisions, and general economies of scale in our personnel-related costs and other costs associated to our support and operations departments.

10

Operating Expenses:

Research and Development, Net

	Nine Months Ended March 31,				Nine Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Research and development, net	$	23,999	$	15,317	$	8,682	56.7	%

Research and development, net increased by $8.7 million, or 56.7%, in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015, primarily due to an increase in personnel-related costs of $5.9 million triggered by increased headcount. The increase in headcount reflects our continued investment in enhancing our existing products as well as development associated with bringing new products to market. In addition, other directly related overhead and travels costs, material consumption, use of contractors and subcontractors and depreciation of lab equipment increased by $0.8 million, $0.5 million, $0.4 million and $0.3 million, respectively, and we recorded $0.8 million less in grants from the Office of the Chief Scientist of Israel in the nine months ended March 31, 2016 as compared to the nine months ended March, 2015.

Sales and Marketing

	Nine Months Ended March 31,				Nine Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Sales and marketing	$	25,903	$	17,541	$	8,362	47.7	%

Sales and marketing expenses increased by $8.4 million, or 47.7%, in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015, primarily due to an increase in personnel-related costs of $6.1 million resulting from an increase in headcount supporting our growth in the U.S. and Europe. In addition, expenses related to travel and other directly related overhead costs, trade shows and marketing activities, the use of contractors and subcontractors and depreciation and other expenses increased by $1.1 million, $0.7 million, $0.3 million and $0.2 million, respectively, in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015.

General and Administrative

	Nine Months Ended March 31,				Nine Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
General and administrative	$	9,066	$	4,270	$	4,796	112.3	%

General and administrative expenses increased by $4.8 million, or 112.3%, in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015, primarily due to an increase in personnel-related costs of $2.6 million related to (i) higher headcount in the legal, finance, human resources, and information technology department functions required of a fast-growing public company and (ii) increased expenses related to equity-based compensation, changes in management compensation and growth in vacation accruals, which resulted from changes in compensation. In addition, costs related to being a public company, accounting, tax, legal and information systems consulting and other directly related overhead costs, travels and accrual to doubtful debt increased by $1.0 million, $0.6 million and $0.6 million, respectively, in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015.

11

Financial Income (Expenses), Net

	Nine Months Ended March 31,					Nine Months Ended March 31, 2015 to 2016
	2016			2015		Change
	(Dollars in thousands)
Financial expenses (income)	$	(998	)	$	3,378	$	(4,376	)	N/A

Financial income was $1.0 million in the nine months ended March 31, 2016 compared to financial expenses of $3.4 million in the nine months ended March 31, 2015, primarily due to (i) a decrease of $2.4 million in expensesrelated to remeasurement of certain warrants granted to Kreos in relation to the Kreos Loan in the nine months ended March 31, 2015 as compared to the nine months ended March 31, 2016, due to the full exercise of the warrants, (ii) income of $1.2 million generated from foreign exchange fluctuations in the nine months ended March 31, 2016 compared to expenses of $0.1 million from foreign exchange fluctuations of the Euro and the New Israeli Shekel against the U.S. Dollar in the nine months ended March 31, 2015, (iii) a decrease of $0.9 million of interest expenses from the full repayment of our borrowings under our revolving line of credit with SVB  (described below) and interest on the Kreos Loan, and (iv) $0.3 million interest income, net of accretion (amortization) of discount (premium) on marketable securities and time deposits in the nine months ended March 31, 2016 compared to none in the nine months ended March 31, 2015. This was offset by an increase of $0.5 million costs related to hedging transactions in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015.

Taxes on Income (Tax Benefit)

	Nine Months Ended March 31,					Nine Months Ended March 31, 2015 to 2016
	2016			2015		Change
	(Dollars in thousands)
Taxes on income (tax benefit)	$	(4,463	)	$	1,146	$	(5,609	)	N/A

Tax benefit was $4.5 million in the nine months ended March 31, 2016 compared to taxes on income of $1.1 million in the nine months ended March 31, 2015, primarily due to the establishment of a $6.6 million deferred tax asset in the nine months ended March 31, 2016 offset by an increase of $1.0 million in current tax expenses in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015.

Net Income

	Nine Months Ended March 31,				Nine Months Ended March 31, 2015 to 2016
	2016		2015		Change
	(Dollars in thousands)
Net income	$	59,336	$	11,860	$	47,476	400.3	%

As a result of the factors discussed above, net income increased by $47.5 million, or 400.3% in the nine months ended March 31, 2016 as compared to the nine months ended March 31, 2015.

12

Liquidity and Capital Resources

The following table shows our cash flow from operating activities, investing activities and financing activities for the stated periods:

	Three Months Ended March 31,						Nine Months Ended March 31,
	2016			2015			2016			2015
Net cash provided by (used in) operating activities		15,342		$	(13,044	)	$	34,392		$	(3,635	)
Net cash used in investing activities		(38,473	)		(5,280	)		(97,510	)		(10,251	)
Net cash provided by financing activities		1,167			129,800			2,639			139,457
Increase (decrease) in cash and cash equivalents	$	(21,964	)	$	111,476		$	(60,479	)	$	125,571

As of March 31, 2016, our cash and cash equivalents were $84.1 million. This amount does not include $87.2 million invested in available for sale marketable securities and $0.9 million of restricted cash (primarily held to secure bank guarantees securing office lease payments). On March 31, 2015, we consummated our initial public offering in which we sold 8,050,000 shares of our common stock at a price of $18.00 per share, resulting in net proceeds of $131.2 million, after deducting underwriting discounts and commissions and $3.6 million in offering expenses paid by us. We maintain the net proceeds received from our initial public offering as well as cash provided by operating activites in cash and cash equivalents and available-for-sale marketable securities. We believe that cash provided by operating activities as well as our cash and cash equivalents, including the net proceeds from our initial public offering, will be sufficient to meet our anticipated cash needs for at least the next 12 months.

Operating Activities

For the nine months ended March 31, 2016, cash provided by operating activities was $34.4 million derived mainly from a net income of $59.3 million that included $9.6 million of non-cash expenses. An increase of $14.8 million in warranty obligations, $5.9 million in deferred revenues and $5.5 million accruals for employees and a decrease of $13.2 million in prepaid expenses and other receivables was offset by an increase of $20.7 million in trade receivables, $11.4 million in inventories, $6.6 million in deferred tax assets and a decrease of $35.2 million in trade payables and other accounts payable.

For the nine months ended March 31, 2015, cash used in operating activities was $3.6 million mainly due to an increase of $39.1 million in inventory, $26.0 million in trade receivables, $12.2 million in prepaid expenses and other receivables, which was offset by a net income of $11.9 million that included $4.5 million of non-cash expenses, an increase of $44.6 million in trade payables and other accounts payable, $9.7 million in warranty obligations, $2.1 million in deferred revenues and $0.9 million accruals for employees.

Investing Activities

During the nine months ended March 31, 2016, net cash used in investing activities was $97.5 million, of which $88.9 million was invested in available-for-sale marketable securities, $11.5 million related to capital investments in laboratory equipment, end of line testing equipment, manufacturing tools and leasehold improvements and $0.8 million related to intangible assets investment. This was offset by a $2.7 million repayment of a security deposit held to secure payments under our previous office lease and $1.0 million from the maturities of available-for-sale marketable securities.

During the nine months ended March 31, 2015, net cash used in investing activities was $10.3 million, of which $8.3 million was related to capital investments in laboratory equipment, end of line testing equipment, manufacturing tools and leasehold improvements, and $2.0 million related to security deposits held to secure letters of credit to vendors and bank guarantees securing office lease payments.

Financing Activities

For the nine months ended March 31, 2016, net cash provided by financing activities was $2.6 million, all attributed to cash received from the exercise of employee and non-employee stock options.

For the nine months ended March 31, 2015, net cash provided by financing activities was $139.5 million, of which $133.9 million was net proceeds from our initial public offering , $24.7 million was net proceeds from our Series E convertible preferred stock issuance and $23.0 million was from short-term borrowings under our revolving line of credit with SVB, offset by $36.3 million of repayment of the revolving line of credit with SVB and $5.9 million of repayment of a term loan.

13

Debt Obligations

Revolving Line of Credit

In February 2015, we amended and restated a revolving line of credit agreement with Silicon Valley Bank (“SVB”), which permits aggregate borrowings of up to $40 million in an amount not to exceed 80% of the eligible accounts receivable and bears interest, payable monthly, at SVB’s prime rate plus a margin of 0.5% to 2.0%. The revolving line of credit will terminate, and outstanding borrowings will be payable, on December 31, 2016. As of March 31, 2016, we had no outstanding borrowings under our $40 million revolving line of credit with SVB.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

ITEM 3QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in foreign currency exchange rates, customer concentrations and interest rates. We do not hold or issue financial instruments for trading purposes.

Foreign Currency Exchange Risk

Approximately 21.3% and 21.9% of our revenues for the nine months ended March 31, 2016 and 2015, respectively, were earned in non-U.S. Dollar-denominated currencies, principally the Euro. Our expenses are generally denominated in the currencies in which our operations are located, primarily the U.S. Dollar and New Israeli Shekel, and to a lesser extent the Euro. Our New Israeli Shekel-denominated expenses consist primarily of personnel and overhead costs. Our consolidated results of operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. A hypothetical 10% change in foreign currency exchange rates during the nine months ended March 31, 2016, between the Euro and the U.S. Dollar would increase or decrease our net income by $6.3 million for the nine months ended March 31, 2016. A hypothetical 10% change in foreign currency exchange rates during the nine months ended March 31, 2016, between the New Israeli Shekel and the U.S. Dollar would increase or decrease our net income by $2.1 million for the nine months ended March 31, 2016.

For purposes of our consolidated financial statements, local currency assets and liabilities are translated at the rate of exchange to the U.S. Dollar on the balance sheet date and local currency revenues and expenses are translated at the exchange rate as of the date of the transaction or at the average exchange rate to the U.S. Dollar during the reporting period.

To date, we have used derivative financial instruments, specifically foreign currency forward contracts, to manage exposure to foreign currency risks by hedging a portion of our account receivable balances denominated in Euros expected to be paid within nine months. Our foreign currency forward contracts are expected to mitigate exchange rate changes related to the hedged assets. We do not use derivative financial instruments for speculative or trading purposes.

We had cash and cash equivalents of $84.1 million and available-for-sale marketable securities with an estimated fair value of $87.2 million on March 31, 2016, which securities were held for working capital purposes. We do not enter into investments for trading or speculative purposes. Since most of our cash and cash equivalents are held in U.S. Dollar-denominated money market funds, we believe that our cash and cash equivalents do not have any material exposure to changes in exchange rates.

14

Concentrations of Major Customers

Our trade accounts receivables potentially expose us to a concentration of credit risk with our major customers. As of March 31, 2016, three major customers accounted for approximately 38.5% of our consolidated trade receivables balance. We currently do not foresee a credit risk associated with these receivables.

ITEM 4CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 31, 2016. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective and operating to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and to provide reasonable assurance that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management was not required to perform an annual assessment of the effectiveness of our internal control over financial reporting for the year ending June 30, 2015, but we expect that management will be required to perform such an assessment for the year ending June 30, 2016.  We have not engaged an independent registered accounting firm to perform an audit of our internal control over financial reporting as of any balance sheet date or for any period reported in our financial statements. Our independent public registered accounting firm will first be required to attest to the effectiveness of our internal control over financial reporting for our Annual Report on Form 10-K for the first year we are no longer an “emerging growth company.”

Changes in Internal Control over Financial Reporting

Based on an evaluation by our chief executive officer and chief financial officer, such officers concluded that there have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1LEGAL PROCEEDINGS

In the normal course of business, we may from time to time be named as a party to various legal claims, actions and complaints. It is impossible to predict with certainty whether any resulting liability would have a material adverse effect on our financial position, results of operations or cash flows.

ITEM 1A RISK FACTORS

There have been no material changes to  the risk factors as described in Part I, Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended June 30, 2015 and in Part I, Item 1A, "Risk Factors," in our Quarterly Report on Form 10-Q for the six months ended December 31, 2015 .

15

ITEM 2UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(a) Recent Sales of Unregistered Securities

None.

(b) Use of Proceeds

On March 25, 2015, our registration statement on Form S-1 (No. 333-202159) was declared effective for our initial public offering and on March 31, 2015, we consummated the initial public offering consisting of 8,050,000 shares of our common stock at a public offering price of $18.00 per share. The offering terminated after the sale of all securities registered in the offering. Goldman, Sachs & Co. acted as joint book-running managers for the offering. Needham & Company, Canaccord Genuity Inc. and Roth Capital Partners acted as co-managers. As a result of the offering, we received total net offering proceeds of $131.2 million, after deducting total expenses of $13.7 million, consisting of underwriting discounts and commissions of $10.1 million and offering related expenses paid by us of $3.6 million. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities, or (iii) any of our affiliates.

We maintain the funds received in cash and cash equivalents and available-for sale marketable securitties.Our principal uses of these proceeds from the initial public offering is general corporate purposes, including working capital and expansion of our business into additional markets. The funds have not been used to make payments directly or indirectly to (i) any of the Company’s officers or directors or their associates, (ii) any persons owning 10% or more of any class of the Company’s equity securities, or (iii) any of the Company’s affiliates.

ITEM 3DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5OTHER INFORMATION

None.

16

ITEM 6EXHIBITS

Exhibit No.	Description	Incorporation by Reference (where a report is indicated below, that document has been previously filed with the SEC and the applicable exhibit is incorporated by reference thereto)
31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a).	Filed with this report.
31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a).	Filed with this report.
32.1	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed with this report
32.2	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed with this report.
101.INS	XBRL Instance Document	Filed with this report.
101.SCH	XBRL Taxonomy Extension Schema Document	Filed with this report.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	Filed with this report.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	Filed with this report.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document	Filed with this report.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	Filed with this report.

17

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 10, 2016	SOLAREDGE TECHNOLOGIES, INC. /s/ Guy Sella Guy Sella Chief Executive Officer and Chairman of the Board (Principal Executive Officer)
Date: May 10, 2016	/s/ Ronen Faier Ronen Faier Chief Financial Officer (Principal Financial and Accounting Officer)

18

EX-31.1

Exhibit 31.1

I, Guy Sella, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of SolarEdge Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2016

/s/ Guy Sella

Guy Sella

Chief Executive Officer and Chairman of the Board

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

I, Ronen Faier, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of SolarEdge Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2016

/s/ Ronen Faier

Ronen Faier

Chief Financial Officer

(Principal Financial Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Guy Sella, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of SolarEdge Technologies, Inc. for the quarterly period ended March 31, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of SolarEdge Technologies, Inc.

May 10, 2016

/s/Guy Sella

Guy Sella

Chief Executive Officer and Chairman of the Board

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Ronen Faier, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of SolarEdge Technologies, Inc. for the quarterly period ended March 31, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of SolarEdge Technologies, Inc.

May 10, 2016

/s/ RONEN FAIER

Ronen Faier

Chief Financial Officer

XML

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2016	May. 01, 2016
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Registrant Name	SolarEdge Technologies Inc
Entity Central Index Key	0001419612
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		40,730,849

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 84,070	$ 144,750
Restricted cash	944	$ 3,639
Marketable Securities	44,059
Trade receivables, net	56,145	$ 35,428
Prepaid expenses and other accounts receivable	18,613	32,645
Inventories	85,514	73,950
Total current assets	289,345	290,412
PROPERTY AND EQUIPMENT, NET	26,213	$ 14,717
LONG-TERM ASSETS:
Long-term marketable securities	43,151
Long-term prepaid expenses and lease deposits	440	$ 529
Deferred tax assets, net	6,486
Intangible assets, net	737
Total long-term assets	50,814	$ 529
Total assets	366,372	305,658
CURRENT LIABILITIES:
Trade payables	45,138	80,684
Employees and payroll accruals	12,358	6,814
Warranty obligations	13,510	9,431
Deferred revenues	2,642	1,676
Accrued expenses and other accounts payable	7,797	6,987
Total current liabilities	81,445	105,592
LONG-TERM LIABILITIES
Warranty obligations	33,149	22,448
Deferred revenues	13,266	8,289
Lease incentive obligation	2,265	2,385
Total long-term liabilities	48,680	33,122
Share capital
Common stock of $0.0001 par value - Authorized: 125,000,000 shares as of March 31, 2016 (unaudited) and June 30, 2015; issued and outstanding: 40,684,496 and 39,297,539 shares as of March 31, 2016 (unaudited) and June 30, 2015, respectively.	4	4
Additional paid-in capital	296,480	287,152
Accumulated other comprehensive income (loss)	417	(222)
Accumulated deficit	(60,654)	(119,990)
Total stockholders' equity	236,247	166,944
Total liabilities and stockholders' equity	$ 366,372	$ 305,658

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2016	Jun. 30, 2015
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized shares	125,000,000	125,000,000
Common stock, issued shares	40,684,496	39,297,539
Common stock, outstanding shares	40,684,496	39,297,539

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues	$ 125,205	$ 86,399	$ 365,091	$ 226,658
Cost of revenues	84,471	62,698	252,248	173,146
Gross profit	40,734	23,701	112,843	53,512
Operating expenses:
Research and development, net	8,709	5,490	23,999	15,317
Sales and marketing	8,826	6,422	25,903	17,541
General and administrative	3,460	1,990	9,066	4,270
Total operating expenses	20,995	13,902	58,968	37,128
Operating income	19,739	9,799	53,875	16,384
Financial income (expenses), net	2,029	(3,436)	998	(3,378)
Income before taxes on income	21,768	6,363	54,873	13,006
Taxes on income (tax benefit)	969	398	(4,463)	1,146
Net income	$ 20,799	$ 5,965	$ 59,336	$ 11,860
Net basic earnings per share of common stock	$ 0.52	$ 0.01	$ 1.49	$ 0.02
Net diluted earnings per share of common stock	$ 0.47	$ 0.01	$ 1.34	$ 0.01
Weighted average number of shares used in computing net basic earnings per share of common stock	40,362,093	2,822,893	39,725,227	2,817,090
Weighted average number of shares used in computing net diluted earnings per share of common stock	44,577,901	7,099,046	44,347,071	5,534,903

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 20,799	$ 5,965	$ 59,336	$ 11,860
Available-for-sale securities:
Changes in unrealized losses, net of tax benefit	87		6
Reclassification adjustments for losses included in net income	1		1
Net change	88		7
Cash flow hedges:
Changes in unrealized gains, net of tax expense	668		745
Reclassification adjustments for gains, net of tax expense included in net income	(33)		(35)
Net change	635		710
Foreign currency translation adjustments, net	(13)	$ (102)	(78)	$ (202)
Other comprehensive income (loss)	710	(102)	639	(202)
Comprehensive income	$ 21,509	$ 5,863	$ 59,975	$ 11,658

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows provided by (used in) operating activities:
Net income	$ 59,336	$ 11,860
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	2,601	$ 1,647
Amortization of intangible assets	63
Amortization of premiums on available-for-sale marketable securities	209
Stock-based compensation related to employees and non-employees consultants stock options	$ 6,689	$ 1,750
Financial income, net related to term loan		(992)
Remeasurement of warrants to purchase preferred and common stock		2,065
Changes in assets and liabilities:
Inventories	$ (11,446)	(39,071)
Prepaid expenses and other accounts receivable	13,186	(12,198)
Trade receivables, net	(20,681)	$ (25,993)
Deferred tax assets, net	(6,627)
Trade payables	(35,554)	$ 39,604
Employees and payroll accruals	5,517	883
Warranty obligations	14,780	9,718
Deferred revenues	5,942	2,116
Accrued expenses and other accounts payable	497	2,733
Lease incentive obligation	(120)	2,243
Net cash provided by (used in) operating activities	34,392	(3,635)
Cash flows used in investing activities:
Purchase of property and equipment	(11,545)	$ (8,254)
Purchase of intangible assets	(800)
Decrease (increase) in restricted cash	2,695	$ (1,973)
Decrease (increase) in short and long-term lease deposits	23	$ (24)
Purchases of available-for-sale marketable securities	(88,883)
Maturities of available-for-sale marketable securities	1,000
Net cash used in investing activities	$ (97,510)	$ (10,251)
Cash flows from financing activities:
Proceeds from short-term bank loans		23,000
Repayments of short-term loan		(36,326)
Repayments of term loan		(5,919)
Proceeds from issuance of stock		24,712
Proceeds from IPO, net		133,944
Proceeds from exercise of employees and non-employees consultants stock options	$ 2,639	46
Net cash provided by financing activities	2,639	139,457
Increase (decrease) in cash and cash equivalents	(60,479)	125,571
Cash and cash equivalents at the beginning of the period	144,750	9,754
Erosion due to exchange rate differences	(201)	(121)
Cash and cash equivalents at the end of the period	$ 84,070	135,204
Supplemental disclosure of non-cash financing activities:
Issuance expenses not paid in cash		$ 2,489

XML

GENERAL

9 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1:-  GENERAL

a. SolarEdge Technologies, Inc. (the “Company”) and its subsidiaries design, develop, and sell an intelligent inverter solution designed to maximize power generation at the individual photovoltaic (“PV”) module level while lowering the cost of energy produced by the solar PV system and providing comprehensive and advanced safety features. The Company’s products consist mainly of (i) power optimizers designed to maximize energy throughput from each and every module through constant tracking of Maximum Power Point individually per module, (ii) inverters which invert direct current (DC) from the PV module to alternating current (AC) and (iii) a related cloud-based monitoring platform, that collects and processes information from the power optimizers and inverters of a solar PV system to enable customers and system owners, as applicable, to monitor and manage the solar PV systems. The Company operates its business itself and through its wholly-owned subsidiaries: SolarEdge Technologies Ltd. in Israel; SolarEdge Technologies GmbH in Germany; SolarEdge Technologies (China) Co., Ltd in China; SolarEdge Technologies (Australia) PTY Ltd. in Australia; SolarEdge Technologies (Canada) Ltd. in Canada; SolarEdge Technologies (Holland) B.V. in the Netherlands; SolarEdge Technologies (UK) Ltd in United Kingdom; SolarEdge Technologies (Japan) Co., Ltd. in Japan, SolarEdge Technologies (France) SARL in France, SolarEdge Technologies Italy S.R.L. in Italy and SolarEdge Technologies (Bulgaria) Ltd. in Bulgaria (collectively, the “subsidiaries”). Except for SolarEdge Technologies Ltd in Israel, which carries out the research and development, management of manufacturing, global sales and support and management activities, the other subsidiaries are engaged solely in selling, marketing and support activities.  The Company was incorporated in Delaware in August 2006 and began commercial sale of its products in January 2010.

b. Recent accounting pronouncements: Inventory: In July 2015, the Financial Accounting Standards Board (“FASB”) issued “ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory”, which changes the measurement principles for inventory from the lower of cost or market to the lower of cost and net realizable value. Net realizable value is defined as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.” ASU 2015-11 eliminates the guidance that required entities to consider replacement cost or net realizable value less an approximately normal profit margin in the subsequent measurement of inventory when cost is determined on a first-in, first-out or average cost basis. The provisions of ASU 2015-11 are effective for public entities with fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the impact of ASU 2015-11 on its consolidated financial position, consolidated results of operations, and consolidated cash flows

Deferred Taxes:

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes, which will require that the presentation of deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company has adopted this guidance effective December 31, 2015. The adoption only impacted the presentation in its consolidated financial statements and related disclosure. No prior periods were retroactively adjusted.

c. The significant accounting policies applied in the Company’s audited annual consolidated financial statements as of June 30, 2015 are applied consistently in these financial statements.

d. Basis of Presentation: The accompanying unaudited consolidated interim financial statements have been prepared in accordance with Article 10 of Regulation S-X, “Interim Financial Statements” and the rules and regulations for Form 10-Q of the Securities and Exchange Commission (the “SEC”). Pursuant to those rules and regulations, the Company has condensed or omitted certain information and footnote disclosure it normally includes in its annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly present its consolidated financial position, results of operations and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the 2015 consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for its fiscal year ended June 30, 2015 filed with the SEC on August 20, 2015 (the “2015 Form 10-K”). There have been no changes in the significant accounting policies from those that were disclosed in the audited consolidated financial statements for the fiscal year ended June 30, 2015 included in the 2015 Form 10-K.

e. The Company depends on two contract manufacturers and several limited or single source component suppliers. Reliance on these vendors makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs. Two vendors collectively account for 72% (unaudited) and 79% of the Company’s total trade payables as of March 31, 2016 (unaudited) and June 30, 2015, respectively.

f. Marketable Securities: Marketable securities consist of corporate and governmental bonds. The Company determines the appropriate classification of marketable securities at the time of purchase and re-evaluates such designation at each balance sheet date. In accordance with FASB ASC No. 320 “Investments- Debt and Equity Securities”, the Company classifies marketable securities as available-for-sale. Available-for-sale securities are stated at fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss), a separate component of stockholders’ equity, net of taxes. Realized gains and losses on sales of marketable securities, as determined on a specific identification basis, are included in financial income (expenses), net. The amortized cost of marketable securities is adjusted for amortization of premium and accretion of discount to maturity, both of which, together with interest, are included in financial income (expenses), net. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company recognizes an impairment charge when a decline in the fair value of its investments in debt securities below the cost basis of such securities is judged to be other-than-temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company’s intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. If the Company does not intend to sell the security or it is not more likely than not that it will be required to sell the security before it recovers in value, the Company must estimate the net present value of cash flows expected to be collected. If the amortized cost exceeds the net present value of cash flows, such excess is considered a credit loss and an other-than-temporary impairment has occurred.  For securities that are deemed other-than-temporarily impaired (“OTTI”), the amount of impairment is recognized in the statement of operations and is limited to the amount related to credit losses, while impairment related to other factors is recognized in other comprehensive income (loss). The Company did not recognize OTTI on its marketable securities during the nine months ended on March 31, 2016.

g. Derivative financial instruments: The Company accounts for derivatives and hedging based on ASC 815 (“Derivatives and Hedging”). ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship.

To protect against the increase in value of forecasted foreign currency cash flows resulting from salary and lease payments of its Israeli facilities denominated in the Israeli currency, the New Israeli Shekel (“NIS”), during the three and nine months ended March 31, 2016, the Company instituted a foreign currency cash flow hedging program. The Company hedges portions of the anticipated payroll and lease payments denominated in NIS for a period of one to twelve months with hedging contracts. Accordingly, when the dollar strengthens against the foreign currencies, the decline in present value of future foreign currency expenses is offset by losses in the fair value of the hedging contracts. Conversely, when the dollar weakens, the increase in the present value of future foreign currency cash flows is offset by gains in the fair value of the hedging contracts. These hedging contracts are designated as cash flow hedges, as defined by ASC 815 and are all effective hedges of these expenses.

In accordance with ASC 815, for derivative instruments that are designated and qualify as a cash flow hedge (i.e. hedging the exposure to variability in expected future cash flows that is attributable to a particular risk), the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Any gain or loss on a derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item is recognized in current earnings during the period of change.

In addition to the above mentioned cash flow hedges transactions, the Company also entered into derivative instrument arrangements to hedge the Company’s exposure to currencies other than the U.S. dollar. These derivative instruments are not designated as cash flows hedges, as defined by ASC 815, and therefore all gains and losses, resulting from fair value remeasurement, were recorded immediately in the statement of operations, as financial income (expenses).

As of March 31, 2016, the Company entered into forward contracts and put and call options to sell U.S. dollars and Euros in the amount of $19,547 and €2,500,000, respectively. These hedging contracts do not contain any credit-risk-related contingency features. See Note 6 for information on the fair value of these hedging contracts.

The fair value of derivative assets and derivative liabilities as of March 31, 2016 was $854 and $5, respectively which was recorded in other accounts receivable and prepaid expenses in the consolidated balance sheets.

The amount recorded as gain in the cost of revenues expenses under the consolidated statements of operations for the three and the nine months ended March 31, 2016 (unaudited) resulted from the above referenced hedging transactions was $8.

The amount recorded as gain in the research and development, net expenses under the consolidated statements of operations for the three and the nine months ended March 31, 2016 (unaudited) resulted from the above referenced hedging transactions was $18.

The amount recorded as gain in the sales and marketing expenses under the consolidated statements of operations for the three and the nine months ended March 31, 2016 (unaudited) resulted from the above referenced hedging transactions was $11.

The amount recorded as gain in the general and administrative expenses under the consolidated statements of operations for the three and the nine months ended March 31, 2016 (unaudited) resulted from the above referenced hedging transactions was $3 and $6, respectively.

The fair value of the outstanding derivative instruments as of March 31, 2016 (unaudited) and June 30, 2015 is summarized below:

		Fair Value of Derivative Instruments
	Balance Sheet Location	As of March 31, 2016 (unaudited)		As of June 30, 2015
Derivative Assets
Foreign exchange      forward contracts      and put and call options	Prepaid expenses and other accounts receivable (*)		849		859
Total			849		859

(*) Estimated to be reclassified into earnings until December 31, 2016.

The effect of derivative instruments in cash flow hedging transactions on income and other comprehensive income (“OCI”) for the three and the nine months ended March 31, 2016 and 2015 is summarized below:

	Gains on Derivatives Recognized in OCI		Gains on Derivatives Recognized in OCI
	for the three months ended		for the nine months ended
	March 31,		March 31,
	2016	2015	2016	2015
	(unaudited)		(unaudited)
Foreign exchange      forward contracts      and put and call      options	668	-	745	-

	Gains Reclassified from OCI into Income		Gains Reclassified from OCI into Income
	for the three months ended		for the nine months ended
	March 31,		March 31,
	2016	2015	2016	2015
	(unaudited)		(unaudited)
Foreign exchange      forward contracts      and put and call      options	33	-	35	-

h. Intangible assets:

On March 9, 2015, the Company and Beacon Power LLC, a Delaware limited liability company (“Beacon”) entered into a patent purchase agreement under which the Company agreed to purchase all rights in the patents. In July 2015, the Company completed the purchase of the patents for $800.

The patents are stated at cost, net of accumulated amortization. Amortization is calculated by the straight-line method over 10 years, which represents the estimated useful lives of the patents.

Amortization expenses for the three and the nine months ended March 31, 2016 (unaudited) were $21 and $63, respectively.

i. Accumulated other comprehensive income (loss):

The following table summarizes the changes in accumulated balances of other comprehensive income (loss), net of taxes, for the three months ended March 31, 2016 (unaudited):

	Unrealized gains (losses) on available-for-sale marketable securities			Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total
Beginning balance		(81	)		75			(287	)		(293	)
Other comprehensive income (loss) before reclassifications		87			668			(13	)		742
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1			(33	)		-			(32	)
Net current period other comprehensive income (loss)		88			635			(13	)		710
Ending balance		7			710			(300	)		417

The following table summarizes the changes in accumulated balances of other comprehensive loss, net of taxes, for the nine months ended March 31, 2016 (unaudited):

	Unrealized gains (losses) on available-for-sale marketable securities		Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total
Beginning balance		-		-			(222	)		(222	)
Other comprehensive income (loss) before reclassifications		6		745			(78	)		673
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1		(35	)		-			(34	)
Net current period other comprehensive income (loss)		7		710			(78	)		639
Ending balance		7		710			(300	)		417

XML

MARKETABLE SECURITIES

9 Months Ended

Mar. 31, 2016

Investments, Debt and Equity Securities [Abstract]

MARKETABLE SECURITIES

NOTE 2:- MARKETABLE SECURITIES

The following is a summary of available-for-sale marketable securities at March 31, 2016 (unaudited):

	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair value
Corporate bonds	$	82,183	$	55	$	36	$	82,202
Governmental bonds	$	5,015	$	3	$	10	$	5,008
	$	87,198	$	58	$	46	$	87,210

As of June 30, 2015, the Company had no investments in marketable securities.

The amortized cost of available-for-sale marketable securities at March 31, 2016, by contractual maturities, is shown below:

	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair value
Due in one year or less	$	44,050	$	21	$	12	$	44,059
Due after one year to two years	$	43,148	$	37	$	34	$	43,151
	$	87,198	$	58	$	46	$	87,210

As of March 31, 2016, management believes the impairments are not other than temporary and therefore the impairment losses were recorded in accumulated other comprehensive income (loss). The Company has no intent to sell these securities and it is more likely than not that the Company will not be required to sell these securities prior to the recovery of the entire amortized cost basis.

As of March 31, 2016 (unaudited), there was 32 securities in a loss position.

The total fair value of marketable securities with outstanding unrealized losses as of March 31, 2016 (unaudited) amounted to $40,147, while the unrealized losses for these marketable securities amounted to $46.

XML

INVENTORIES

9 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 3:- INVENTORIES

	March 31, 2016		June 30, 2015
	(unaudited)
Raw materials	$	10,639	$	14,405
Finished goods		74,875		59,545
	$	85,514	$	73,950

XML

WARRANTY OBLIGATIONS

9 Months Ended

Mar. 31, 2016

Product Warranties Disclosures [Abstract]

WARRANTY OBLIGATIONS

NOTE 4:- WARRANTY OBLIGATIONS

Changes in the Company’s product warranty liability for the nine months ended March 31, 2016 and 2015 were as follows:

	Nine months ended March 31,
	2016			2015
	(unaudited)
Balance, at beginning of period	$	31,879		$	18,181
Additions and adjustments to cost of revenues		21,250			13,456
Usage and current warranty expenses		(6,470	)		(3,738	)
Balance, at end of period		46,659			27,899
Less current portion		13,510			7,661
Long term portion	$	33,149		$	20,238

XML

REVOLVING CREDIT LINE

9 Months Ended

Mar. 31, 2016

Line of Credit Facility [Abstract]

REVOLVING CREDIT LINE

NOTE 5:- REVOLVING CREDIT LINE

In June 2011, the Company entered into an agreement for a revolving line of credit from a bank lender (the "Bank Lender").

On February 17, 2015, the Company amended and restated the agreement with the Bank Lender for its revolving line of credit, which permits aggregate borrowings of up to $40 million in an amount not to exceed 80% of the eligible accounts receivable and bears interest, payable monthly, at the Bank Lender’s prime rate plus a margin of 0.5% to 2.0%. The Company’s revolving line of credit will terminate, and outstanding borrowings will be payable, on December 31, 2016.

In connection with the revolving line of credit, the Company granted the Bank Lender security interests in substantially all of the Company’s assets, including a first-priority security interest in the Company’s trade receivables, cash and cash equivalents. Financial covenants contained in the amended and restated agreement require the Company to maintain EBITDA and liquidity at specified levels.

The Company is required to maintain liquidity (defined as unrestricted and unencumbered cash, plus availability in the amended and restated agreement) of $6,750.

The amended and restated agreement also contains covenants that restrict the Company’s ability to dispose of assets, engage in business combinations (or permit a subsidiary to engage in business combinations), grant liens, borrow money, or pay dividends.

As of March 31, 2016 (unaudited) and June 30, 2015, the Company was in compliance with all applicable covenants in the amended and restated agreement.

As of March 31, 2016 (unaudited), the Company had no outstanding borrowings pursuant to this revolving line of credit.

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 6:- FAIR VALUE MEASUREMENTS

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level to classify them for each reporting period. There have been no transfers between fair value measurements levels during the nine months ended March 31, 2016.

The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value:

Level 1-	Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2-	Include other inputs that are directly or indirectly observable in the marketplace.

Level 3- Unobservable inputs which are supported by little or no market activity.

The following table sets forth the Company’s assets that were measured at fair value as of March 31, 2016 (unaudited) by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	March 31, 2016 (unaudited)		Level 1		Level 2		Level 3
Cash equivalents:
Money market mutual funds	$	17,520	$	17,520		-		-
Derivative instruments asset	$	849		-	$	849		-
Short-term marketable securities:
Corporate bonds	$	43,055		-	$	43,055		-
Governmental bonds	$	1,004		-	$	1,004		-
Long-term marketable securities:
Corporate bonds	$	39,147		-	$	39,147		-
Governmental bonds	$	4,004		-	$	4,004		-

The following table sets forth the Company’s assets that were measured at fair value as of June 30, 2015 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	June 30, 2015		Level 1		Level 2		Level 3
Derivative instruments asset	$	859		-	$	859		-

In addition to the assets described above, the Company’s financial instruments also include cash and cash equivalents, restricted and short-term deposits, trade receivables, other accounts receivable, trade payables, accrued expenses and other payables. The fair value of these financial instruments was not materially different from their carrying values on Mach 31, 2016 due to the short-term maturity of these instruments.

XML

LEASE INCENTIVE OBLIGATION

9 Months Ended

Mar. 31, 2016

Leases [Abstract]

LEASE INCENTIVE OBLIGATION

NOTE 7:- LEASE INCENTIVE OBLIGATION

The Company has an operating lease agreement for a building in Herziliya, Israel. In connection with this lease, the Company and its third party lessor (the "Lessor"), agreed that the Lessor would reimburse approximately $2,938 for certain leasehold improvements made by the Company.

As of March 31, 2016 (unaudited), the Company received in cash $2,917 from the Lessor in connection with such leasehold improvements. These leasehold improvements are accounted for as a lease incentive obligation, which is recorded under long-term liabilities, net of the current portion recorded in accrued expenses and other accounts payable under current liabilities. The lease incentive obligation is being amortized over the life of the lease and as a reduction to rent expense. As of March 31, 2016, the net amortized amount of lease incentive obligation recorded under long-term liabilities is $2,265.

XML

COMMITMENTS AND CONTINGENT LIABILITIES

9 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 8:- COMMITMENTS AND CONTINGENT LIABILITIES

a. Lease commitments:

The Company and its subsidiaries lease their operating facilities under non-cancelable operating lease agreements, which expire over the next nine years, with the last ending in December 2024.

The future minimum lease commitments of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises that are in effect as of March 31, 2016 (unaudited), are as follows:

Year ended June 30,	(unaudited)
2016		598
2017		2,252
2018		2,148
2019		2,003
2020 and thereafter		8,707
		15,708

Rent expenses for the nine months ended March 31, 2016 (unaudited) and 2015 (unaudited) were approximately $1,653 and $1,222, respectively.

b. Guarantees:

As of March 31, 2016 (unaudited), contingent liabilities exist regarding guarantees in the amount of $631, $53 and $85 in respect of office rent lease agreements, customs transactions and credit card limits, respectively.

c. Royalty and Governmental commitments:

As of March 31, 2016 (unaudited), the aggregate contingent liability to the Binational Industrial Research and Development Foundation (BIRD-F) amounted to approximately $1,132 which would be payable by the Company if it ever did generate revenues from such project.

As of March 31, 2016 (unaudited), the aggregate contingent liability to the Office of the Chief Scientist (the OCS) amounted to $782.

d. Contractual purchase obligations:

The Company has contractual obligations to purchase certain goods and raw materials. These contractual purchase obligations relate to certain inventories held by contract manufacturers and purchase orders initiated by the contract manufacturers and suppliers, which cannot be canceled without penalty. The Company utilizes third parties to manufacture its products. In addition, it acquires raw materials or other goods and services, including product components, by issuing to suppliers authorizations to purchase based on its projected demand and manufacturing needs. As of March 31, 2016 (unaudited), the Company had non-cancelable purchase obligations totaling approximately $84,275, of which the Company already recorded a provision for loss in the amount of $1,860.

e. Legal claims:

From time to time, the Company may be involved in various claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. These accruals are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular matter.

XML

STOCK CAPITAL

9 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK CAPITAL

NOTE 9:- STOCK CAPITAL

a. On March 23, 2015, the Company's board of directors and the requisite holders of the Company's capital stock consented to a 1-for-3 reverse stock split of the Company's common stock. As a result of the reverse stock split, (i) every 3 shares of authorized, issued and outstanding common stock was decreased to one share of authorized, issued and outstanding common stock, (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased on a 1-for-3 basis, (iii) all share prices and exercise prices were proportionately increased. All of the share numbers, share prices, and exercise prices have been adjusted within these consolidated financial statements, on a retroactive basis, to reflect this 1-for-3 reverse stock split.

b. Common Stock:

	Authorized		Issued and outstanding
	Number of shares
	March 31, 2016	June 30, 2015	March 31, 2016	June 30, 2015
	(unaudited)		(unaudited)
Stock of $0.0001 par value:
Common stock	125,000,000	125,000,000	40,684,496	39,297,539

c. Stock Incentive plans:

The Company’s 2007 Global Incentive Plan (the “2007 Plan”) was adopted by the board of directors on August 30, 2007. On March 31, 2015, upon consummation of the Company’s Initial Public Offering (“IPO”), the 2007 Plan was terminated and no further awards will be granted thereunder. All outstanding awards will continue to be governed by their existing terms and 379,358 available options for future grant were transferred to the Company’s 2015 Global Incentive Plan (the “2015 Plan”) and are reserved for future issuances under the 2015 Plan.

The 2015 Plan became effective upon the consummation of the IPO. The 2015 Plan provides for the grant of options, RSUs and other share-based awards to directors, employees, officers and consultants of the Company and its subsidiaries. The Share Reserve will automatically increase on January 1st of each year during the term of the 2015 Plan commencing on January 1st of the year following the year in which the 2015 Plan becomes effective in an amount equal to five percent (5%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year; provided, however, that our board of directors may provide that there will not be a January 1st increase in the Share Reserve in a given year or that the increase will be less than five percent (5%) of the shares of common stock outstanding on the preceding December 31st.

The aggregate maximum number of shares of common stock that may be issued on the exercise of incentive stock options is ten million (10,000,000).

As of March 31, 2016 (unaudited), a total of 3,827,117 (unaudited) shares of common stock were reserved for issuance under the 2015 Plan (the “Share Reserve”).

As of March 31, 2016 (unaudited), an aggregate of 2,731,852 shares of common stock are available for future grant under the 2015 Plan.

d. Options granted to employees and members of the board of directors:

A summary of the activity in the options granted to employees and members of the board of directors for the nine months ended March 31, 2016 (unaudited) and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	Options			price		in years		value
Outstanding as of July 1, 2015		6,034,782			3.14		7.06		200,438
Granted		228,800			25.09
Exercised		(1,230,923	)		2.05
Forfeited or expired		(46,971	)		3.86
Outstanding as of March 31, 2016		4,985,688			4.41		6.75		103,375
Vested and expected to vest as of March 31, 2016		4,798,492			4.33		6.73		99,877
Exercisable as of March 31, 2016		3,099,118			2.88		5.65		68,974

The aggregate intrinsic value represents the total intrinsic value (the difference between the fair value of the Company’s common stock as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period. The total intrinsic value of options exercised during the nine months ended on March 31, 2016 (unaudited) was $27,602.

The weighted average grant date fair values of options granted to employees and executive directors during the nine months ended March 31, 2016 (unaudited) was $25.09.

The options outstanding as of March 31, 2016 (unaudited) have been separated into exercise price ranges as follows:

			Weighted		Options		Weighted
	Outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	March 31,		contractual		March 31,		contractual
price	2016		life in years		2016		life in years
$0.87 - $1.50		770,940		2.89		770,940		2.89
$1.68 - $2.46		1,465,040		5.49		1,408,292		5.46
$3.03 - $3.96		542,018		7.53		279,270		7.24
$5.01		1,945,562		8.66		602,296		8.66
$9.36		33,328		8.84		9,720		8.84
$25.09		228,800		9.39		28,600		9.39
		4,985,688		6.75		3,099,118		5.65

e. A summary of the activity in the RSUs granted to employees and members of the board of directors for the nine months ended March 31, 2016 (unaudited), is as follows:

	No. of Options			Weighted average grant date fair value
Unvested as of July 1, 2015		67,440			25.09
Granted		807,656			24.45
Vested		(112,591	)		24.57
Forfeited		(40,965	)		24.07
Unvested as of March 31, 2016		721,540			24.38

f.  Options and RSUs issued to non-employee consultants:

The Company has granted options and RSUs to non-employee consultants as of March 31, 2016 (unaudited) as follows:

	Outstanding				Exercisable
	as of				as of
Issuance	March 31,		Exercise		March 31,		Exercisable
date	2016		price		2016		through
July 31, 2008		33,333		0.87		33,333	July 31, 2018
October 24, 2012		5,166		2.46		4,333	October 24, 2022
January 23, 2013		3,333		3.03		2,778	January 23, 2023
January 27, 2014		4,698		3.51		2,226	January 27, 2024
May 1, 2014		6,000		3.51		3,167	May 1, 2024
September 17, 2014		10,830		3.96		4,790	September 17, 2024
October 29, 2014		5,788		5.01		1,010	October 29, 2024
August 19, 2015		28,167		0.00		-
November 8, 2015		4,167		0.00		-
		101,482				51,637

The Company had accounted for its options and RSUs granted to non-employee consultants under the fair value method of ASC 505-50. In connection with the grant of options and RSUs to non-employee consultants, the Company recorded stock compensation expenses in the three months ended March 31, 2016 (unaudited) and 2015 (unaudited) in the amounts $91, and $228, respectively, and stock compensation expenses in the nine months ended March 31, 2016 and 2015 in the amounts $464 and $331, respectively

g. Stock-based compensation expense for employees and consultants:

The Company recognized stock-based compensation expenses related to options and RSUs granted to employees and non-employees in the consolidated statement of operations for the three and six months ended on March 31, 2016 (unaudited) and 2015 (unaudited), as follows:

	Three months ended March 31,				Nine months ended March 31,
	2016		2015		2016		2015
Cost of revenues	$	246	$	140	$	635	$	254
Research and development		724		183		1,637		449
Selling and marketing		842		292		2,207		545
General and administrative		819		355		2,210		502
Total stock-based compensation expense	$	2,631	$	970	$	6,689	$	1,750

As of March 31, 2016 (unaudited), there was a total unrecognized compensation expense of $26,384 related to non-vested equity-based compensation arrangements granted under the Company’s plans. These expenses are expected to be recognized during the period from April 1, 2016 through February 29, 2020.

XML

INCOME TAXES

9 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 10:- INCOME TAXES

a. Taxes on income (tax benefit) are comprised as follows:

	Three months ended March 31,					Nine months ended March 31,
	2016			2015		2016			2015
	Unaudited					Unaudited
Current year taxes	$	1,069		$	398	$	2,380		$	1,146
Previous year taxes		-			-		(216	)		-
Deferred tax expense (income)		(100	)		-		(6,627	)		-
Taxes on income (tax benefit)	$	969		$	398	$	(4,463	)	$	1,146

b. Deferred income taxes:

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

Significant components of the Company’s deferred tax liabilities and assets are as follows:

	March 31,		June 30,
	2016		2015
	(Unaudited)
Assets in respect of:
Carryforward tax losses	$	-	$	23,033
Research and Development carryforward expenses- temporary differences		4,488		5,173
Stock-based compensation		548		-
Other reserves		1,450		1,346
		6,486		29,552
Valuation allowance (1)		-		(29,552	)
Net deferred tax assets	$	6,486	$	-

(1) ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluated the net deferred tax assets for each separate tax entity. As of June 30, 2015, the Company concluded that it is not more likely than not that the net deferred tax assets will be realized and a full valuation allowance has been recorded against these assets. The Company's estimate of future book-taxable income considers available evidence, both positive and negative, about its operating businesses and investments, including an aggregation of individual projections for each significant operating business and investment, estimated apportionment factors for state and local taxing jurisdictions and includes all future years that the Company estimated it would have available net operating loss carryforwards.

During the second fiscal quarter of 2016, the Company determined that the positive evidence outweighs the negative evidence for deferred tax assets and concluded that these deferred tax assets are realizable on a "more likely than not" basis. This determination was mainly due to expected future results of positive operations and earnings history.

XML

BASIC AND DILUTED NET EARNINGS PER SHARE

9 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

BASIC AND DILUTED NET EARNINGS PER SHARE

NOTE 11:- BASIC AND DILUTED NET EARNINGS PER SHARE

Basic net earnings per share is computed by dividing the net earnings by the weighted-average number of shares of common stock outstanding during the period.

The total weighted average number of shares of common stock related to the outstanding stock options, convertible preferred stock and warrants to purchase convertible preferred stock and common stock, excluded from the calculation of diluted net earnings per share due to their anti-dilutive effect, was 0 and 28,351,707 for the three months ended March 31, 2016 (unaudited) and 2015 (unaudited), respectively and 12,945 and 27,378,784 for the nine months ended March 31, 2016 (unaudited) and 2015 (unaudited), respectively

Basic and diluted earnings per share is presented in conformity with the two-class method for participating securities for the periods prior to their conversion. Under this method, the earnings per share for each class of shares are calculated assuming 100% of the Company's earnings are distributed as dividends to each class of shares based on their contractual rights.

The following table presents the computation of basic and diluted net earnings per share for the periods presented:

	Three months ended March 31,					Nine months ended March 31,
	2016		2015			2016		2015
	(unaudited)					(unaudited)
Numerator:
Net income		20,799		5,965			59,336		11,860
Dividends accumulated for the period		-		(5,923	)		-		(11,817	)
Net income available to holders of common stock		20,799		42			59,336		43
Denominator:
Shares used in computing net earnings per share of common stock, basic		40,362,093		2,822,893			39,725,227		2,817,090
Numerator:
Net income		20,799		5,965			59,336		11,860
Dividends accumulated for the period		-		(5,872	)		-		(11,782	)
Net income available to holders of common stock		20,799		93			59,336		78
Denominator:
Shares used in computing net earnings per share of common stock, diluted		44,577,901		7,099,046			44,347,071		5,534,903

XML

CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

9 Months Ended

Mar. 31, 2016

Risks and Uncertainties [Abstract]

CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

NOTE 12:- CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

a. For the three month period ended March 31, 2016 (unaudited), the Company had two major customers that accounted for approximately 26.7% of its consolidated revenues.

For the nine month period ended March 31, 2016 (unaudited), the Company had three major customers that accounted for approximately 34.9% of its consolidated revenues.

For the year ended June 30, 2015, the Company had one major customer that accounted for 24.6% of its consolidated revenues.

b. As of March 31, 2016 (unaudited), three customers accounted for 38.5% of the Company’s net accounts receivable and as of June 30, 2015, one customer accounted for 30.0% of the Company’s net accounts receivable.

XML

GENERAL (Tables)

9 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Fair Value of Derivative Instruments

		Fair Value of Derivative Instruments
	Balance Sheet Location	As of March 31, 2016 (unaudited)		As of June 30, 2015
Derivative Assets
Foreign exchange      forward contracts      and put and call options	Prepaid expenses and other accounts receivable (*)		849		859
Total			849		859

Schedule of Derivative Instruments Gains Recognized in OCI

	Gains on Derivatives Recognized in OCI		Gains on Derivatives Recognized in OCI
	for the three months ended		for the nine months ended
	March 31,		March 31,
	2016	2015	2016	2015
	(unaudited)		(unaudited)
Foreign exchange      forward contracts      and put and call      options	668	-	745	-

	Gains Reclassified from OCI into Income		Gains Reclassified from OCI into Income
	for the three months ended		for the nine months ended
	March 31,		March 31,
	2016	2015	2016	2015
	(unaudited)		(unaudited)
Foreign exchange      forward contracts      and put and call      options	33	-	35	-

Schedule of Derivative Gains (Losses) Reclassified From OCI Into Income

	Unrealized gains (losses) on available-for-sale marketable securities			Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total
Beginning balance		(81	)		75			(287	)		(293	)
Other comprehensive income (loss) before reclassifications		87			668			(13	)		742
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1			(33	)		-			(32	)
Net current period other comprehensive income (loss)		88			635			(13	)		710
Ending balance		7			710			(300	)		417

The following table summarizes the changes in accumulated balances of other comprehensive loss, net of taxes, for the nine months ended March 31, 2016 (unaudited):

	Unrealized gains (losses) on available-for-sale marketable securities		Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total
Beginning balance		-		-			(222	)		(222	)
Other comprehensive income (loss) before reclassifications		6		745			(78	)		673
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1		(35	)		-			(34	)
Net current period other comprehensive income (loss)		7		710			(78	)		639
Ending balance		7		710			(300	)		417

XML

MARKETABLE SECURITIES (Tables)

9 Months Ended

Mar. 31, 2016

Investments, Debt and Equity Securities [Abstract]

Summary of Available-For-Sale Marketable Securities

	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair value
Corporate bonds	$	82,183	$	55	$	36	$	82,202
Governmental bonds	$	5,015	$	3	$	10	$	5,008
	$	87,198	$	58	$	46	$	87,210

Summary of amortized cost of available-for-sale marketable securities

	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair value
Due in one year or less	$	44,050	$	21	$	12	$	44,059
Due after one year to two years	$	43,148	$	37	$	34	$	43,151
	$	87,198	$	58	$	46	$	87,210

XML

INVENTORIES (Tables)

9 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Schedule of inventories

	March 31, 2016		June 30, 2015
	(unaudited)
Raw materials	$	10,639	$	14,405
Finished goods		74,875		59,545
	$	85,514	$	73,950

XML

WARRANTY OBLIGATIONS (Tables)

9 Months Ended

Mar. 31, 2016

Product Warranties Disclosures [Abstract]

Schedule of warranty obligations

	Nine months ended March 31,
	2016			2015
	(unaudited)
Balance, at beginning of period	$	31,879		$	18,181
Additions and adjustments to cost of revenues		21,250			13,456
Usage and current warranty expenses		(6,470	)		(3,738	)
Balance, at end of period		46,659			27,899
Less current portion		13,510			7,661
Long term portion	$	33,149		$	20,238

XML

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Schedule of assets and liabilities measured at fair value by level

	Balance as of		Fair value measurements
Description	March 31, 2016 (unaudited)		Level 1		Level 2		Level 3
Cash equivalents:
Money market mutual funds	$	17,520	$	17,520		-		-
Derivative instruments asset	$	849		-	$	849		-
Short-term marketable securities:
Corporate bonds	$	43,055		-	$	43,055		-
Governmental bonds	$	1,004		-	$	1,004		-
Long-term marketable securities:
Corporate bonds	$	39,147		-	$	39,147		-
Governmental bonds	$	4,004		-	$	4,004		-

The following table sets forth the Company’s assets that were measured at fair value as of June 30, 2015 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	June 30, 2015		Level 1		Level 2		Level 3
Derivative instruments asset	$	859		-	$	859		-

XML

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)

9 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease commitments

Year ended June 30,	(unaudited)
2016		598
2017		2,252
2018		2,148
2019		2,003
2020 and thereafter		8,707
		15,708

XML

STOCK CAPITAL (Tables)

9 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of composition of common stock capital

	Authorized		Issued and outstanding
	Number of shares
	March 31, 2016	June 30, 2015	March 31, 2016	June 30, 2015
	(unaudited)		(unaudited)
Stock of $0.0001 par value:
Common stock	125,000,000	125,000,000	40,684,496	39,297,539

XML

STOCK CAPITAL (Tables)

9 Months Ended

Mar. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of recognized stock-based compensation expenses

	Three months ended March 31,				Nine months ended March 31,
	2016		2015		2016		2015
Cost of revenues	$	246	$	140	$	635	$	254
Research and development		724		183		1,637		449
Selling and marketing		842		292		2,207		545
General and administrative		819		355		2,210		502
Total stock-based compensation expense	$	2,631	$	970	$	6,689	$	1,750

Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of the activity in the share options

	No. of Options			Weighted average grant date fair value
Unvested as of July 1, 2015		67,440			25.09
Granted		807,656			24.45
Vested		(112,591	)		24.57
Forfeited		(40,965	)		24.07
Unvested as of March 31, 2016		721,540			24.38

Schedule of exercise price range of options

	Outstanding				Exercisable
	as of				as of
Issuance	March 31,		Exercise		March 31,		Exercisable
date	2016		price		2016		through
July 31, 2008		33,333		0.87		33,333	July 31, 2018
October 24, 2012		5,166		2.46		4,333	October 24, 2022
January 23, 2013		3,333		3.03		2,778	January 23, 2023
January 27, 2014		4,698		3.51		2,226	January 27, 2024
May 1, 2014		6,000		3.51		3,167	May 1, 2024
September 17, 2014		10,830		3.96		4,790	September 17, 2024
October 29, 2014		5,788		5.01		1,010	October 29, 2024
August 19, 2015		28,167		0.00		-
November 8, 2015		4,167		0.00		-
		101,482				51,637

Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of the activity in the share options

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	Options			price		in years		value
Outstanding as of July 1, 2015		6,034,782			3.14		7.06		200,438
Granted		228,800			25.09
Exercised		(1,230,923	)		2.05
Forfeited or expired		(46,971	)		3.86
Outstanding as of March 31, 2016		4,985,688			4.41		6.75		103,375
Vested and expected to vest as of March 31, 2016		4,798,492			4.33		6.73		99,877
Exercisable as of March 31, 2016		3,099,118			2.88		5.65		68,974

Schedule of exercise price range of options

			Weighted		Options		Weighted
	Outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	March 31,		contractual		March 31,		contractual
price	2016		life in years		2016		life in years
$0.87 - $1.50		770,940		2.89		770,940		2.89
$1.68 - $2.46		1,465,040		5.49		1,408,292		5.46
$3.03 - $3.96		542,018		7.53		279,270		7.24
$5.01		1,945,562		8.66		602,296		8.66
$9.36		33,328		8.84		9,720		8.84
$25.09		228,800		9.39		28,600		9.39
		4,985,688		6.75		3,099,118		5.65

XML

INCOME TAXES (Tables)

9 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of taxes on income

	Three months ended March 31,					Nine months ended March 31,
	2016			2015		2016			2015
	Unaudited					Unaudited
Current year taxes	$	1,069		$	398	$	2,380		$	1,146
Previous year taxes		-			-		(216	)		-
Deferred tax expense (income)		(100	)		-		(6,627	)		-
Taxes on income (tax benefit)	$	969		$	398	$	(4,463	)	$	1,146

Schedule of deferred tax liabilities and assets

	March 31,		June 30,
	2016		2015
	(Unaudited)
Assets in respect of:
Carryforward tax losses	$	-	$	23,033
Research and Development carryforward expenses- temporary differences		4,488		5,173
Stock-based compensation		548		-
Other reserves		1,450		1,346
		6,486		29,552
Valuation allowance (1)		-		(29,552	)
Net deferred tax assets	$	6,486	$	-

XML

BASIC AND DILUTED NET EARNINGS PER SHARE (Tables)

9 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Schedule of computation of basic and diluted net earnings (loss) per share

	Three months ended March 31,					Nine months ended March 31,
	2016		2015			2016		2015
	(unaudited)					(unaudited)
Numerator:
Net income		20,799		5,965			59,336		11,860
Dividends accumulated for the period		-		(5,923	)		-		(11,817	)
Net income available to holders of common stock		20,799		42			59,336		43
Denominator:
Shares used in computing net earnings per share of common stock, basic		40,362,093		2,822,893			39,725,227		2,817,090
Numerator:
Net income		20,799		5,965			59,336		11,860
Dividends accumulated for the period		-		(5,872	)		-		(11,782	)
Net income available to holders of common stock		20,799		93			59,336		78
Denominator:
Shares used in computing net earnings per share of common stock, diluted		44,577,901		7,099,046			44,347,071		5,534,903

XML

GENERAL (Details) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
		Jul. 31, 2015 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Mar. 31, 2016 USD ($) item	Mar. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)
Organization Consolidation and Presentation of Financial Statements [Line Items]
Number of contract manufacturers | item					2
Number of vendors | item					2
Derivative financial instruments
Notional amount of derivative contract			$ 19,547		$ 19,547
Fair value of derivative assets current			854		854
Fair value of derivative liabilities current			5		5
Net derivative assets			849		849		$ 859
Prepaid expenses and other accounts receivable			18,613		18,613		32,645
Loss from hedging transactions recorded in general and administrative expenses			8		8
Loss from hedging transactions recorded in research and development expenses			18		18
Loss from hedging transactions recorded in sales and marketing expenses			11		11
Foreign exchange forward contracts	[1]		849		849		$ 859
Changes in unrealized gains, net of tax expense			668		745
Consideration paid for patents		$ 800			$ 800
Useful lives of patents					10 years
Amortization expenses			$ 21		$ 63
Accounts Payable [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Concentration risk (as a percent)					73.00%		79.00%

[1] Estimated to be reclassified into earnings during 2016.

XML

GENERAL (Changes in Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Beginning balance	$ (293)		$ (222)
Other comprehensive income (loss) before reclassifications	742		673
Losses (gains) reclassified from accumulated other comprehensive income (loss)	(32)		(34)
Net current period other comprehensive income (loss)	710	$ (102)	639	$ (202)
Ending balance	417		$ 417
Unrealized gains (losses) on available-for-sale marketable securities [Member]
Beginning balance	(81)
Other comprehensive income (loss) before reclassifications	87		$ 6
Losses (gains) reclassified from accumulated other comprehensive income (loss)	1		1
Net current period other comprehensive income (loss)	88		7
Ending balance	7		$ 7
Unrealized gains (losses) on cash flow hedges [Member]
Beginning balance	75
Other comprehensive income (loss) before reclassifications	668		$ 745
Losses (gains) reclassified from accumulated other comprehensive income (loss)	(33)		(35)
Net current period other comprehensive income (loss)	635		710
Ending balance	710		710
Unrealized gains (losses) on foreign currency translation [Member]
Beginning balance	(287)		(222)
Other comprehensive income (loss) before reclassifications	$ (13)		$ (78)
Losses (gains) reclassified from accumulated other comprehensive income (loss)
Net current period other comprehensive income (loss)	$ (13)		$ (78)
Ending balance	$ (300)		$ (300)

XML

MARKETABLE SECURITIES (Details) $ in Thousands	Mar. 31, 2016 USD ($) item
Schedule of Available-for-sale Securities [Line Items]
Due in one year or less, amortized cost	$ 44,050
Due in one year or less, gross unrealized gains	21
Due in one year or less, gross unrealized losses	12
Due in one year or less, fair value	44,059
Due after one year to two years, amortized cost	43,148
Due after one year to two years, gross unrealized gains	37
Due after one year to two years, gross unrealized losses	34
Due after one year to two years, fair value	43,151
Amortized cost	87,198
Gross unrealized gains	58
Gross unrealized losses	46
Fair value	$ 87,210
Number of loss positions | item	32
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 82,183
Gross unrealized gains	55
Gross unrealized losses	36
Fair value	82,202
Governmental bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	5,015
Gross unrealized gains	3
Gross unrealized losses	10
Fair value	$ 5,008

XML

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 10,639	$ 14,405
Finished goods	74,875	59,545
Inventories	$ 85,514	$ 73,950

XML

WARRANTY OBLIGATIONS (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Changes in the Company's product warranty liability
Balance, at beginning of period	$ 31,879	$ 18,181
Additions and adjustments to cost of revenues	21,250	13,456
Usage and current warranty expenses	(6,470)	(3,738)
Balance, at end of period	46,659	27,899
Less current portion	13,510	7,661	$ 9,431
Long term portion	$ 33,149	$ 20,238	$ 22,448

XML

REVOLVING CREDIT LINE (Details) - Revolving Credit Line [Member] - USD ($)
$ in Thousands

9 Months Ended

Feb. 17, 2015

Mar. 31, 2016

Line of Credit Facility [Line Items]

Aggregate borrowings

$ 40,000

Maximum specified percentage of eligible trade receivables considered for determining maximum borrowing capacity

80.00%

Description of variable rate basis

Bank Lender's prime rate

Termination date

Dec. 31, 2016

Amount of liquidity need to maintain

$ 6,750

Minimum [Member]

Line of Credit Facility [Line Items]

Applicable margin (as a percent)

0.50%

Maximum [Member]

Line of Credit Facility [Line Items]

Applicable margin (as a percent)

2.00%

XML

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 17,520
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	17,520
Derivative Financial Instruments, Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	849	$ 859
Derivative Financial Instruments, Assets [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	849	$ 859
Short Term Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	43,055
Short Term Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	43,055
Short Term Governmental Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	1,004
Short Term Governmental Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	1,004
Long Term Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	39,147
Long Term Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	39,147
Long Term Governmental Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	4,004
Long Term Governmental Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 4,004

XML

LEASE INCENTIVE OBLIGATION (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Leases [Abstract]
Operating lease receivable	$ 2,938
Received in cash from the Lessor	2,917
Lease incentive obligation	$ 2,265	$ 2,385

XML

COMMITMENTS AND CONTINGENT LIABILITIES (Schedule of Future Minimum Lease Commitments) (Details) $ in Thousands	Mar. 31, 2016 USD ($)
Future minimum lease commitments
2016	$ 598
2017	2,252
2018	2,148
2019	2,003
2020 and thereafter	8,707
Future minimum lease commitments amount	$ 15,708

XML

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Lease commitments) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Lease commitments
Contract term	10 years
Rent expenses	$ 1,653	$ 1,222

XML

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Guarantees) (Details) $ in Thousands	Mar. 31, 2016 USD ($)
Office Rent Lease Agreements [Member]
Guarantor Obligations [Line Items]
Guarantees amount	$ 631
Customs Transactions [Member]
Guarantor Obligations [Line Items]
Guarantees amount	53
Credit Card Limits [Member]
Guarantor Obligations [Line Items]
Guarantees amount	$ 85

XML

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Royalty, Governmental, and Contractual purchase obligations) (Details) $ in Thousands	Mar. 31, 2016 USD ($)
Royalty commitments
Aggregate contingent liability to the BIRD-F amount	$ 1,132
Governmental commitments
Governmental commitments amount	782
Contractual purchase obligations
Non-cancelable purchase obligations	84,275
Provision for contractual inventory purchase obligations	$ 1,860

XML

STOCK CAPITAL (Common Stock) (Details)	9 Months Ended
	Mar. 31, 2016 $ / shares shares	Jun. 30, 2015 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Reverse stock split ratio	0.33
Common stock capital
Par value | $ / shares	$ 0.0001	$ 0.0001
Authorized	125,000,000	125,000,000
Common stock, issued shares	40,684,496	39,297,539
Common stock, outstanding shares	40,684,496	39,297,539

XML

STOCK CAPITAL (Stock option plans) (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Dec. 31, 2014	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of options exercised		$ 27,602
Unrecognized compensation expense		$ 26,384
2007 Plan, Transferred to 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options are available for future grant under the plan		379,358
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options reserved for issuance under the plan		3,827,117
Percentage of common shares increase automatically in each year		5.00%
2015 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of common shares increase automatically in each year	5.00%
Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options are available for future grant under the plan		10,000,000
Employee Stock Purchase Plan [Member] | 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options are available for future grant under the plan		2,731,852
Options And RSUs [Member] | Employees and Members of Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair values options granted to employees and executive directors		$ 25.09
Restricted Stock Units (RSUs) [Member] | Employees and Members of Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair values options granted to employees and executive directors		$ 24.45

XML

STOCK CAPITAL (Summary of activity in the share options) (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Aggregate intrinsic Value
Exercised	$ 27,602
Option [Member] | Employees and Members of Board of Directors [Member]
Number of options
Outstanding as of July 1, 2015	6,034,782
Granted	228,800
Exercised	(1,230,923)
Forfeited or expired	46,971
Outstanding as of March 31, 2016	4,985,688	6,034,782
Weighted average exercise price
Outstanding as of July 1, 2015	$ 3.14
Granted	25.09
Exercised	2.05
Forfeited or expired	3.86
Outstanding as of March 31, 2016	$ 4.41	$ 3.14
Weighted average remaining contractual term in years
Outstanding	6 years 9 months	7 years 22 days
Aggregate intrinsic Value
Outstanding as of July 1, 2015	$ 200,438
Outstanding as of March 31, 2016	$ 103,375	$ 200,438
Vested and expected to vest at the end of the period
Number of options	4,798,492
Weighted average exercise price	$ 4.33
Weighted average remaining contractual term in years	6 years 8 months 23 days
Aggregate intrinsic Value	$ 99,877
Exercisable as of March 31, 2016
Weighted average exercise price	$ 2.88
Weighted average remaining contractual term in years	5 years 7 months 24 days
Aggregate intrinsic Value	$ 68,974

XML

STOCK CAPITAL (Schedule of exercise price ranges) (Details) - Employees and Members of Board of Directors [Member]	9 Months Ended
	Mar. 31, 2016 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding	4,985,688
Weighted average remaining contractual Life in years	6 years 9 months
Exercisable	3,099,118
Weighted average remaining contractual Life in years	5 years 7 months 24 days
$0.50 - $1.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, lower | $ / shares	$ 0.87
Range of exercise price, upper | $ / shares	$ 1.50
Outstanding	770,940
Weighted average remaining contractual Life in years	2 years 10 months 21 days
Exercisable	770,940
Weighted average remaining contractual Life in years	2 years 10 months 21 days
$1.68 - $2.46 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, lower | $ / shares	$ 1.68
Range of exercise price, upper | $ / shares	$ 2.46
Outstanding	1,465,040
Weighted average remaining contractual Life in years	5 years 5 months 27 days
Exercisable	1,408,292
Weighted average remaining contractual Life in years	5 years 5 months 16 days
$3.03 - $3.96 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, lower | $ / shares	$ 3.03
Range of exercise price, upper | $ / shares	$ 3.96
Outstanding	542,018
Weighted average remaining contractual Life in years	7 years 6 months 11 days
Exercisable	279,270
Weighted average remaining contractual Life in years	7 years 2 months 27 days
$5.01 - $5.04 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price | $ / shares	$ 5.01
Outstanding	1,945,562
Weighted average remaining contractual Life in years	8 years 7 months 28 days
Exercisable	602,296
Weighted average remaining contractual Life in years	8 years 7 months 28 days
$9.36 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price | $ / shares	$ 9.36
Outstanding	33,328
Weighted average remaining contractual Life in years	8 years 10 months 2 days
Exercisable	9,720
Weighted average remaining contractual Life in years	8 years 10 months 2 days
$25.09 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price | $ / shares	$ 25.09
Outstanding	228,800
Weighted average remaining contractual Life in years	9 years 4 months 21 days
Exercisable	28,600
Weighted average remaining contractual Life in years	9 years 4 months 21 days

XML

STOCK CAPITAL (Summary of the activity in the RSUs) (Details) - Restricted Stock Units (RSUs) [Member] - Employees and Members of Board of Directors [Member]	9 Months Ended
	Mar. 31, 2016 $ / shares shares
No. of Options
Unvested as of July 1, 2015 | shares	67,440
Granted | shares	807,656
Vested | shares	(112,591)
Forfeited | shares	(40,965)
Unvested as of March 31, 2016 | shares	721,540
Weighted average grant date fair value
Unvested as of July 1, 2015 | $ / shares	$ 25.09
Granted | $ / shares	24.45
Vested | $ / shares	24.57
Forfeited | $ / shares	24.07
Unvested as of March 31, 2016 | $ / shares	$ 24.38

XML

STOCK CAPITAL (Options and RSUs issued to non-employee consultants) (Details) - Options And RSUs [Member] - Nonemployee Consultants [Member]	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	101,482
Exercisable at the end of the period	51,637
July 31, 2008 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	33,333
Exercise price | $ / shares	$ 0.87
Exercisable at the end of the period	33,333
October 24, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	5,166
Exercise price | $ / shares	$ 2.46
Exercisable at the end of the period	4,333
January 23, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	3,333
Exercise price | $ / shares	$ 3.03
Exercisable at the end of the period	2,778
January 27, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	4,698
Exercise price | $ / shares	$ 3.51
Exercisable at the end of the period	2,226
May 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	6,000
Exercise price | $ / shares	$ 3.51
Exercisable at the end of the period	3,167
September 17, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	10,830
Exercise price | $ / shares	$ 3.96
Exercisable at the end of the period	4,790
October 29, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	5,788
Exercise price | $ / shares	$ 5.01
Exercisable at the end of the period	1,010
August 19, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	28,167
Exercise price | $ / shares	$ 0.00
Exercisable at the end of the period
November 8, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period	4,167
Exercise price | $ / shares	$ 0.00
Exercisable at the end of the period

XML

STOCK CAPITAL (Schedule of stock-based compensation expense for employees and consultants) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 2,631	$ 970	$ 6,689	$ 1,750
Nonemployee Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	91	228	464	331
Cost of revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	246	140	635	254
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	724	183	1,637	449
Selling and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	842	292	2,207	545
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 819	$ 355	$ 2,210	$ 502

XML

INCOME TAXES (Schedule of Taxes on Income) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Current year taxes	$ 1,069	$ 398	$ 2,380	$ 1,146
Previous year taxes			(216)
Deferred tax expense (income)	$ (100)		(6,627)
Taxes on income (tax benefit)	$ 969	$ 398	$ (4,463)	$ 1,146

XML

INCOME TAXES (Schedule of Deferred Tax Liabilities And Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Assets in respect of:
Carryforward tax losses		$ 23,033
Research and Development carryforward expenses- temporary differences	$ 4,488	$ 5,173
Stock-based compensation	548
Other reserves	1,450	$ 1,346
Deferred tax assets, gross	$ 6,486	29,552
Valuation allowance		$ (29,552)
Net deferred tax assets	$ 6,486

XML

BASIC AND DILUTED NET EARNINGS PER SHARE (Narrative) (Details) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Total weighted average number of shares related to the outstanding stock options, convertible preferred stock and warrants to purchase convertible preferred stock and common stock, excluded from the calculation of diluted net earnings (loss) per share due to their anti-dilutive effect	0	28,351,707	12,945	27,378,784

XML

BASIC AND DILUTED NET EARNINGS PER SHARE (Schedule of Computation of Basic and Diluted Net Earnings (Loss) Per Share) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net income	$ 20,799	$ 5,965	$ 59,336	$ 11,860
Dividends accumulated for the period		(5,923)		(11,817)
Net income available to holders of common stock	$ 20,799	$ 42	$ 59,336	$ 43
Denominator:
Shares used in computing net earnings (loss) per share of common stock, basic (in shares)	40,362,093	2,822,893	39,725,227	2,817,090
Numerator:
Net income	$ 20,799	$ 5,965	$ 59,336	$ 11,860
Dividends accumulated for the period		(5,872)		(11,782)
Net income available to holders of common stock	$ 20,799	$ 93	$ 59,336	$ 78
Denominator:
Shares used in computing net earnings per share of common stock, diluted	44,577,901	7,099,046	44,347,071	5,534,903

XML

CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS (Details)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2016	Jun. 30, 2015
Revenues [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)	26.70%	34.90%
Revenues [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)	26.70%	34.90%
Revenues [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)	26.70%
Revenues [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)			24.60%
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)		38.50%
Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)		38.50%
Accounts Receivable [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)		38.50%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk (as a percent)			30.00%